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Introduction: Mycoplasmas of animals 
Classification and phylogeny 
The mycoplasmas (class Mollicutes) represent a wide spectrum of phylogenetically 
related parasitic bacteria. The Mollicutes group includes the smallest known self-
replicating organisms carrying the smallest number of genes that are characterized by 
the lacking of a cell wall. There is no wonder, therefore, that mycoplasmas have a 
special appeal to those interested in the definition of the minimal set of genes 
essential for life considering this as an important step on the way of reaching the goal 
of defining in molecular terms the entire machinery of a self-replicating cell1. 
Recently the attention of researchers was also focused on the study of the pathogenic 
mechanism of Mycoplasma and on its ability to evade the host immune response by 
antigenic variation of surface proteins2. Mollicutes phylogeny has been controversial 
for a long time. Thanks to the 16S rRNA sequence data Woese and co-workers3 were 
able to define the classification that is currently in use. A simplified list of the most 
common genera is listed in Fig. 1. 
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Figure 1: Taxonomy and characteristics of the genera of the class Mollicutes. 
Modified from Razin S et al, (2002). Molecular biology and pathogenicity of 
mycoplasmas4, p. 1096. 
The ancestral mycoplasma arose from the Streptococcus phylogenetic branch about 
600 million years ago. The mycoplasma phylogenetic tree split later into two major 
branches: one branch (the “AAA” branch) led to the Asteroleplasma, Anaeroplasma, 
and Acholeplasma branches, and the other (the “SEM” branch) led to the 
Spiroplasma, Entomoplasma, and Mycoplasma branches4. 
The members of the class Mollicutes are characterized by their small genome size 
(0.58 – 2.2 Mbp), a low G+C content (23 – 40 mol%) of the genome and a 
permanent lack of a cell wall, but a deeper insight into their classification reveals a 
discrepancy between taxonomy and phylogeny, due to the fact that the genus 
Mycoplasma is distributed in four of the five phylogenetic groups and three of these 
groups also contain mollicutes of other genera. However is widely accepted that 
phylogeny is a naturally dynamic subject, because of the numerous parameters that 
influence its results. 
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The aim of this project was the evaluation of the host T cell immune response 
elicited against M. agalactiae infection and vaccination, but little is known about the 
immune dialogue between M. agalactiae and its host, particularly the T cells reaction 
to this pathogen; hereby is depicted a panorama of the immune interaction with the 
host immune system of other better-known Mycoplasmas.  
Pathogenesis and immunomodulation by Mycoplasma and its 
components 
Invasion of nonphagocytic cells 
Among Mycoplasma species, many are classified as commensal organisms. They 
may inhabit mucosal tissues of animals without causing a disease. Also pathogenic 
mycoplasmas are often able to interact with host cells without causing acute 
cytopathic effects, therefore they can be defined as the “ideal parasites”1, being able 
to establish with the host an harmonic equilibrium. 
Pathogenic mycoplasmas have a pronounced affinity for mucosal tissues and 
consequently show a predilection for the respiratory system, mammary gland, serous 
membranes and the urogenital tract. Although it is believed that mycoplasmas remain 
attached to the surface of epithelial cells, some mycoplasmas have evolved 
mechanisms for invading host cells that are not naturally phagocytic. Invasion of 
nonphagocytic host cells, even if for a short period of time, may provide 
mycoplasmas the ability to cross mucosal barriers and gain access to internal tissues. 
The ability to invade and live within host cells has been intensively studied in the 
case of Mycoplasma penetrans5. This microorganism adheres to cell surfaces, deeply 
penetrates into the cell using a tip-like structure and extensive invasion of 
the mycoplasma into the cytoplasm may kill the cells. 
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Other mycoplasmas, known to be surface parasites, such as M. fermentans6, M. 
pneumoniae7, M. genitalium8, M. galliseplticum9 and M. synoviae10 were also 
proved, under certain conditions, to reside within non-phagocytic cells. The 
mechanism of invasion seems to be dependent on the 
polymerization/depolymerization of microtubules or microfilaments1. For example, 
M. penetrans invasion of HeLa cells depends on the capacity of the cells to assemble 
actin microfilaments11, and the entry of M. gallisepticum into the chicken embryo 
fibroblast is inhibited by the microtubule inhibitor nocodazole9. The information 
about the ability of Mycoplasma to multiply within the host cells still needs to be 
investigated. 
Many studies have shown that mycoplasma lipoproteins stimulate monocytes and 
induce the secretion of pro-inflammatory cytokines [ie. tumour necrosis factor α 
(TNF-α), interleukin 6 (IL-6) and IL-1]4,12. Interestingly it happens by a mechanism 
distinct from that of bacterial lipopolysaccharide. Northern (RNA) blot analysis of 
cytokine expression in these cells showed that the induction of IL-1β by 
mycoplasmas involves, unlike that by LPS, posttranscriptional events12. 
Another pathogenic mechanism related to mycoplasma infection is the high-
frequency variation of surface proteins. This aspect will be discussed in the chapter 
related to M. agalactiae. 
Macrophages activation 
Several mycoplasma-derived factors have been reported that act on immune cells in 
various ways, but it was only in the early ’90 that it was described for the first time a 
“high-molecular-weight material” (MDHM) found in M. fermentans able to activate 
macrophages and leading to an indirect formation of cytotoxic T-cells (CTL)13. This 
macrophage activator was demonstrated to be a lipopeptide with only two fatty acids 
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and a free amino terminus and a molecular weight of about 2 kDa. The substance 
was therefore called MALP-2 for Macrophage Activating Lipopeptide of 2 kDa 
molecular weight. The comparison with a similar molecule found in M. hyorinis14 
allowed establishing that it is the lipid portion which imparts the macrophage 
stimulatory activity to these molecules. This activity is very similar to that caused by 
Gram-negative LPS, and the structural similarities between the two classes of 
molecules is surprising (Fig 2). Under certain circumstances, MDHM alone does not 
suffice to trigger cytokine release from THP-1 cells and that additional lipid 
membrane components could be required12, but at least in vitro MALP-2 and LPS 
display the same activities when added to macrophage/monocyte cultures, and both 
substances act at similarly low concentrations. 
 
Figure 2: Structural similarities between Mycoplasmal lipoprotein and bacterial 
lipopolysaccharide. From Razin S, Herrmann R (2002), Molecular biology and 
pathogenicity of mycoplasmas, p. 457. 
 
As previously mentioned, the interaction of monocytes and macrophages with 
several mycoplasmas, including M. fermentans, induces the production of several 
proinflammatory cytokines and mediators, as TNFα, IL-1, IL-6, nitric oxide and 
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oxygen radicals15. Thus proinflammatory cytokines, chemokines and 
prostaglandins16,17 are released in response to MALP-2 and other mycoplasmal 
lipoproteins and lipopeptides. Using a mouse mutant strain (C3H/HeJ) that exhibit a 
very low susceptibility to endotoxin, it was possible to demonstrate that MALP-2 and 
LPS utilize different receptors18,19 
Alternative mechanisms of immunomodulation 
Stuart et al. have reported that heat-inactivated mycoplasmas from some species of 
mycoplasmas can stimulate the expression of MHC class I and class II antigens in 
the mouse myelomonocytic cell line WEHI-3 and that it is due to increase in the 
transcriptional activity of MHC genes20. In a follow up study it was shown that the 
immunomodulatory effect was exerted also in other murine and human cell lines and 
that neither IL-4 nor GM-CSF were required21. Other Authors reported that not only 
the stimulation but also the suppression of expression of MHC class II antigen on 
peritoneal macrophages can be caused by MALP-2 containing preparations22. 
Recently, the over expression of MHC class II molecules was also related to catarrhal 
bronchointerstitial pneumonia caused by M. bovis in cattle23. 
Mycoplasma agalactiae and contagious agalactia  
Mycoplasma agalactiae is the main etiological agent of Contagious agalactia (CA), a 
severe mastitis occurring in small ruminants that represents a relevant constraint for 
milk and cheese production. 
Contagious agalactia is an important disease in the Mediterranean countries of 
Europe, Asia, and North Africa, in the former Soviet Union, in India and Pakistan, 
and in countries of the Middle East. It has also been reported from Australia, South 
Africa, and South America. Although three isolations of M. agalactiae have been 
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reported from the United States, it appears that North American strains are non 
pathogenic and do not cause classical contagious agalatia syndrome.  
Young ruminants become infected directly at suckling, while the adults are 
contaminated during the milking procedures, both by milkers’ hands and by milking 
machinery. The incubation period often varies considerably and can last several 
weeks or months. The main reservoir of the mycoplasmas is the infected animal, in 
which the organisms can persist for over a year after clinical recovery. Infected 
animals which do not show any clinical signs of disease play an important role as 
carriers and are often the main obstacle in the control and eradication of 
mycoplasmoses24. 
In the first stage the disease is visible as mild unilateral or bilateral mastitis with 
warm, swollen, painful parenchyma, later followed by sclerosis and typical reduction 
in size of one or both the organs. Mammary lymph-node is often involved showing 
from mild to marked enlargement in size. The affected animal can also suffer for 
arthritis, which usually involves carpal and tarsal joints, and, in smaller percentage, 
conjunctivitis. Joint fluid is often a rich source of specific antibody, often at a higher 
titre than in the serum, and of the causative mycoplasmas themselves25. M. 
agalactiae can be isolated from milk when mastitis is present; the milk may become 
discolored and granular. Lambs born from affected females can show a wide range of 
symptoms, from null to severe keratoconjunctivitis and polyarthritis (Loria G.R., 
personal communication). New born animals have been also reported to be ataxic, 
and this may be related to septicaemia and/or the presence of the mycoplasma in the 
brain causing a non-purulent encephalomyelitis26. 
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Pathogenic mechanisms of M. agalactiae 
M. agalactiae genome has been entirely sequenced in 2007, when it became easier to 
investigate into the hypothesis that an horizontal gene transfer phenomenon could 
had been be the basis for the exchange of genetic material among mycoplasmas27. M. 
agalactiae strain PG2 genome possesses a typical mollicute genome, with a small 
size (877,438 bp), a low GC content (29.7 moles %), a high gene compaction (88% 
of coding sequence), and UGA preferentially used as a tryptophan codon over UGG. 
It contains 751 coding DNA sequences, half of which have unknown functions or 
encode hypothetical proteins, 66 of which are lipoproteins27. 
As previously reported, the immune response against M. agalactiae and its 
pathogenic mechanisms have never been investigated in the whole. Nevertheless 
some aspects have been evaluated thanks to the information available about other 
mycoplasmas. Different mechanisms are thought to be responsible for M. agalactiae 
pathogenic effects: 
- phase variable related surface proteins (Vpma) 
M. agalactiae possesses a family of lipoproteins named Vpma (Variable Protein of 
Mycoplasma agalactiae) encoded by the correspondent genes27,2. They are 
represented as orthologues in other Mycoplasma species and it was hypothesized that 
they are related in adhesion to host cells28, but the correlation between expression of 
variable surface proteins and adherence rates still seems controversial29. 
Nevertheless, the antigenic variation of M. agalactiae surface antigens could 
reasonably be one of the causes of the loss of efficacy of host immune response. 
- P40: a protein involved in host adhesion 
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Nucleotide sequence-derived amino acid sequence comparisons revealed a similarity 
of P40 to the adhesin P50 of Mycoplasma hominis and to protein P89 of Spiroplasma 
citri, which is expected to be involved in adhesion30. A direct adhesion analysis and 
inhibition experiments of the purified recombinant protein P40 revealed that it is 
involved in adhesion of M. agalactiae to lamb synovial membrane cells, this protein 
is thus part of the pathogenic machinery mounted by M. agalactiae. 
- P48: a probable macrophage stimulatory protein 
As previously mentioned, one of the pathogenic mechanism adopted by 
Mycoplasmas is explicated through macrophages activation. P48, one of the surface 
antigens of M. agalactiae was demonstrated to be an homologous to a MALP 
product of Mycoplasma fermentans31, and thus is implied in the production of several 
proinflammatory cytokines and mediators. 
- Biofilm formation, antimicrobial production and adaptation to specific 
environments. 
McAuliffe et al. have demonstrated that M. agalactiae is able to produce a biofilm 
layer32. Biofilms consist in an extracellular polysaccharide matrix that exhibit 
different phenotypes and organizations. The presence of biofilm increases 
Mycoplasma resistance to heat, desiccation, antimicrobials and, probably, host 
defences. 
Immune response against Mycoplasma agalactiae: state of art 
The immune response against M. agalactiae infection has been initially studied in 
terms of immunoglobulin production. The amount and the timing of antibody 
production was investigated33,34, but results vary depending on the test used and the 
initial amount of live strain used for the infection. According to experimental studies 
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in sheep with M. agalactiae carried out by Buonavoglia et al35, and confirmed in our 
experience36, the presence of antibodies is not detectable by serology until 25-30 
days. In 2007 de la Fe and et al37 analyzed the immunogenicity of two polyvalent 
vaccines against M. agalactiae and Mycoplasma mycoides subsp. Mycoides in terms 
of antibody production, and also in this case there was a slight increase of antibody 
production around day 25 after vaccination, a peak around the second month and a 
persistence of a humoral immunity till day 210 after vaccination. In 2009 and 2010 
Castro Alonzo et al 38,39 correlated the clinical course of mycoplasma mastitis with 
its immune response inoculating mammary glands of lactating goats with a huge 
amount of live M. agalactiae. Authors demonstrate an early involvement of the 
innate immune response, and in particular of neutrophils and macrophages, but 
unable to control mycoplasmal invasion. Post-mortem immunohistochemical 
analyses were then performed to establish the cellular subsets contribution to 
Mycoplasma immunity. Their results confirmed expansion of the CD8 compartment 
at the expense of the CD4 subset leading to a reduced CD4/CD8 ratio 45 days post 
infection. 
Our analyses deepened those performed by Castro Alonzo et al by the using of a 
irradiated antigen of M. agalactiae as stimulus, in order to detect only the cellular 
subsets involved in the defense against Mycoplasma infection. 
Vaccines against M. agalactiae 
Immunity to infection depends on a combination of innate mechanisms and antigen 
specific adaptive responses. The immune system regulates which specific responses 
predominate (humoral vs. cell-mediated) based on the body infected compartment 
(intracellular vs. extracellular) and on cytokine signals present at initial antigen 
contact (Th1 vs. Th2 responses). Disease-causing microbes have virulence 
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mechanisms that resist or evade innate and/or specific immune effector functions. 
Recovery from natural infection or artificial immunization promotes specific long-
term immunity to re-infection (immunological memory). The protective immunity 
against intracellular pathogens mainly involves cellular immunity. A key role in 
immunological memory is played by T lymphocytes. It is well known that naïve T 
cells are those lymphocytes that have never encountered the antigen they are specific 
for. This cell line can be characterized by the presence of the cell surface antigen 
CD45RA. Upon stimulation by specific antigen, naïve T cells lose CD45RA antigen, 
acquire CD45R0 antigen and are finally recruited into the peripheral pool of memory 
T cells40,41. In the study of the immune response elicited against M. agalactiae 
antigen, the attention was focused both in the memory cell populations (CD45R0+– T 
lymphocytes), whose expansion was considered a consequence of the vaccination, 
and in the naïve cell populations (CD45RA+ – T lymphocytes) that could be 
considered the reservoir of memory cells42. 
The first efforts aimed to study the immune response elicited against M. agalactiae 
vaccines have been done many years ago, but were mainly addressed to test the best 
vaccine formulation in terms of inactivation and administration 
procedures43,44,45,46,47. 
Different vaccines have been produced in Italy in the last decades, most of them are 
prepared starting from a monovalent inactivated broth cultures added with different 
kinds of adjuvants which have been gradually improved in immunogenic 
performance. Inactivation is normally performed by addition of small percentage of 
formalin, phenol or more recently saponine-purified products48. Farm vaccines made 
by Istituti Zooprofilattici Sperimentali are veterinary products prepared from wild 
strains directly isolated from the outbreak. These normally are utilized under 
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veterinary prescription to immunize the remaining healthy heads kept in the farm. 
Normally farm vaccines are formalin inactivated and with aluminium hydroxide as 
adjuvant. In Sicily “Mirri vaccine” or “milk inactivated vaccine” was the first 
vaccine ever utilised in Italy49, when selective Mycoplasma media and strain culture 
were not yet available. This vaccine, which still is requested by farmers, was made 
from diluted milk from clinical cases with addition of 4% formalin and aluminium 
hydroxide.  
In the last decade immunogenic proteins of MA have been identified as suitable for 
vaccines against the disease48, but a practical development of a vaccine has been 
actually improbable. Many authors don’t recommend single proteins as potential 
protective vaccine, also due to antigenic variation of the pathogen50,51. Nevertheless 
the real efficacy of currently circulating products (inactivated monovalent vaccines) 
is still doubtful in field conditions37. In Italy the current regulation obliges the farmer 
confining the whole herd until one month from the last clinical case of contagious 
agalactia. Unfortunately, with the exception of few drugs as tylosin and 
new fluoroquinolones that were demonstrated to have a good efficacy in vitro 
(Minimal Inhibitory Concentration52), antibiotics are poorly effective against M. 
agalactiae, and often their action is merely bacteriostatic, rather than bactericidal. A 
more economical alternative is vaccination, which could massively reduce the cost of 
treatment when used as preventive tool. Nowadays, farmers use vaccines also in 
course of outbreak, reporting sometimes a clinical recover also in diseased animals. 
The efficacy of vaccine against CA have been reported for some inactivated 
products,53,46,48, showing data on clinical efficacy (udder changes, milk changes, 
fever, general body conditions, arthritis, conjunctivitis, etc). No data have been 
reported on effectiveness of vaccines in terms of reduction of excretion of the 
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pathogen in the environment. Analogously no information has been collected on 
environmental impact following the use of the vaccine, especially when, in order to 
protect the remaining healthy milking sheep, farmers treat the whole group. 
Aim of the project 
Little is known about the cell-mediated immune response against Mycoplasma 
agalactiae. Empirically it was noted that, under natural conditions, the animal 
infected by this pathogen becomes again susceptible after less than one year. Since in 
Europe the administration of live vaccine is not allowed, the attention was 
traditionally focused on killed microorganisms. The vaccine formulations including 
Mycoplasma inactivated by saponin or ethanol seem to be more effective than 
others54. Nevertheless, a live vaccine has been used in Turkey since the ‘30s, 
obtaining very good results. 
The aim of this project has been the study of the host immune response to M. 
agalactiae, and the comparison of different vaccine formulations, commercially 
available, in order to define which of them is able to confer the best protection. The 
purpose of this work was thus to find a correlate of protection, both during a natural 
infection or after vaccination, and to provide information for veterinary management 
in course of infection about the more effective vaccine. The expansion of T-
lymphocyte subsets has been investigated after in vitro stimulation - with irradiated 
M. agalactiae as a source of antigen - of sheep PBMCs, and intracellular IFN-γ 
presence has been considered as a marker of the activation state. 
Project design 
The project has been divided in two phases: 
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Phase 1- Immune response against M. agalactiae: the immune response against a 
wild strain of M. agalactiae has been evaluated after the experimental infection of 
four lactating sheep. The results were compared to those obtained from an uninfected 
control group. 
Phase 2- Vaccine formulations evaluation: twenty-five lactating sheep were selected 
and divided in five group of five ewes each. Four groups were inoculated with four 
different vaccine formulations. The fifth group did not receive any vaccine. Two 
extra animals were intramammary infected with a wild strain of M. agalactiae and 
used as source of infection for the herd. Clinical symptoms, microbiological data, 
serological data and T-lymphocyte expansion data were analyzed in order to compare 
the efficacy of the different vaccines. 
- Immune response against M. agalactiae 
In the first phase of the project, the percentage of antigen-specific lymphocytes 
positive for intracellular IFN-γ during the infection of sheep with Mycoplasma 
agalactiae was analyzed, culturing peripheral blood mononuclear cells of infected or 
uninfected animals with an irradiated strain of M. agalactiae as in vitro stimulus36. 
Eight healthy ewes, 3–5 year old, belonging to the Comisana dairy breed originating 
from a flock with no history of CA, were selected for the experiment. Four ewes 
were inoculated at day 0 with 1 ml PBS containing 1 × 106 CFU/ml of MA by 
intracanalicular route in both teats. The remaining four sheep were injected with PBS 
alone. During the following 2 months, all animals were monitored weekly for clinical 
changes, specific antibody production, cellular response and pathogen excretion in 
the environment. Blood samples from all the infected and healthy ewes were 
collected at days 0, 15, 30, 45, 60 after infection. After the experiment all the animals 
were clinically monitored until a full remission. 
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- Vaccine formulations evaluation 
Twenty-five animals were divided in five groups of 5 ewes each, while 2 extra sheep 
were chosen (but excluded from data analysis) as reservoir of M. agalactiae for “in 
contact” later challenge37,48. Four groups were inoculated with four different 
vaccines, following manufacturer instructions. The fifth group was not vaccinated 
and was considered as control. The two previously selected animals were used as 
source of infection by inoculation via intracanalicular route of live M. agalactiae 
wild strain. Once vaccination protocols were completed, these “challenge” sheep 
were infected and joint to the flock. All ewes were farmed and milked together as 
one flock, in order to get the same chance to be exposed to the pathogen, resembling 
natural infection. All the animals were monitored once a week for 26 weeks. Whole 
blood samples were collected at days 0, 7, 15, 30, 90 after infection. Milk and swabs 
samples were collected weekly from all ewes; all the data were then statistically 
analysed. Infected animals have been left in the flock until the 4th week of the study, 
than pharmacologically treated to induce drying off and complete recovery. Four 
different vaccines were utilized (Tab 1), all of them were initially compared, 
evaluating those that in our opinion are good indicators, together with immune 
parameters, of vaccine effectiveness: clinical symptoms and pathogen excretion. The 
attention was then focused on three of them, in order to investigate the immune 
response they were able to induce in the host. Pendik vaccine was not included in the 
immune data analysis, because of the restriction dictated by EU in the matter of live 
attenuated vaccine. 
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Group name Vaccine  
 
Number 
of 
animals 
Producer  Inactivation 
procedure 
Adjuvant  
Pendik Live 
attenuated 
5 Pendik Institute  
Turkey 
100 repeated 
passage in eggs  
 
--- 
Saponin Saponin 
vaccine  
5 Pharmaceutical 
company 1 
2 mg/ml 
saponin 
 
--- 
IZSSi Farm vaccine  5 IZS Sicilia, 
Italy 
0.4% formalin 200µl/ml 
Quil A 
Commercial Commercial  5 Pharmaceutical 
company 2 
0.2% formalin Aluminium 
hydroxide 
 
Tab 1: Overview of the vaccine formulations used in this experiment 
Results and conclusions 
Paper 1: Expansion of intracellular IFN-γ positive lymphocytes during 
Mycoplasma agalactiae infection in sheep 
The expansion of antigen-specific IFN-γ positive lymphocytes was evaluated. It was 
initially sustained by CD4+ T cells, that play a role around 15 days after infection. In 
a later phase of infection, CD8/IFN-γ double positive cells increase. γδ T-cells were 
not expanded at any analyzed time point. IFNγ+ T cells disappear 60 days after 
infection, suggesting that antigen specific IFNγ+ T cells, mainly detected in the early 
phase of the disease, could be useful to understand the role of cell-mediated 
immunity during M. agalactiae infection. 
Paper 2: Pathogen excretion and clinical symptoms as indicators for the 
comparative analysis of vaccines efficacy during Mycoplasma agalactiae 
infection 
The data regarding the pathogen excretion in conjunctiva, nasal mucosa and milk 
were analyzed in order to determine the role of the vaccines in conferring protection 
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both to the vaccinated animal (direct protection) and to the herd (indirect 
protection)55. The differences of pathogen excretion thought the milk resulted to be 
statistically significant among groups, and each group showed different ability to 
spread the pathogen in the environment. The sheep belonging to the Pendik and 
Saponin vaccinated groups eliminated significantly less bacteria in the environment 
in comparison with commercial product treated group thus reducing the incidence of 
infection in the herd. This phenomenon has a huge impact in the improving of 
economic management related to the milk products. Similar results were obtained 
considering the incidence of clinical symptoms: live-attenuated vaccine was able to 
confer to the entire group a good clinical protection, and none of them showed 
typical contagious agalactia symptoms. Saponin and IZSSi vaccines conferred a 
similar degree of protection, and only one animal per group showed clinical 
symptoms. Eighty per cent of animals belonging to commercial-vaccine group 
showed severe clinical symptoms. 
Paper 3: Timing of activation of CD4 memory cells as a marker of protection for 
contagious agalactia in the sheep 
Data obtained from this preliminary trial demonstrated that two out of the three 
vaccines used in this study protected sheep from the disease56; memory CD4+ 
Interferon-γ+ T cells increased in the groups protected by these vaccines (p<0.05 
when compared to unprotected groups). On the contrary, memory CD8+ Interferon-γ+ 
T cells increased in non-protected animals (p<0.05). γδ+ Interferon-γ+ T cells reached 
peaks of expansion in infected and in two vaccinated groups indicating that these 
cells aren’t preferentially involved in protection or pathology (p<0.05). Memory 
CD4+ Interferon-γ+ lymphocytes could induce protection from contagious agalactiae 
also activating other effector immune mechanisms such as antibody response and/or 
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antibody dependent cell cytotoxicity. CD8+CD45RO+ Interferon-γ+ lymphocytes 
could induce pathogenic effects killing the protective lymphocyte subset not only by 
themselves, but also cross-talking with other cytotoxic cells such as Natural Killer 
and/or γδ+ T cells. Taken together, our results suggest that antigen-specific 
Interferon-γ+ T cells provide subset correlates of protection and infection with M. 
agalactiae. 
Overall conclusions 
From the data obtained during this project, the cell-mediated immune response 
against M. agalactiae and M. agalactiae vaccines have been elucidated as follows: 
- The natural infection with a live M. agalactiae strain causes an early expansion of 
specific CD4+-IFN-γ+ T-cells, followed by a later expansion of CD8+-IFN-γ+ T-cells, 
30 days post infection. 
- The immune monitoring of vaccinated and infected sheep suggests that timing of 
activation of CD4+-IFN-γ+ memory cells is a key step for the successful protection 
against M. agalactiae. Hereby we propone that CD4+-IFN-γ+-CD45R0+ T-cells could 
be used to determine vaccine efficacy 
- The pathogen excretion in the environment was used as parameter, together with 
clinical symptoms, to evaluate vaccine efficacy, and live attenuated vaccine, in spite 
of the limitation dictated by EU, was the most protective vaccine, while among 
inactivated vaccine, the one treated with saponin conferred the best protection after 
the experimental challenge. 
This was the first work aimed to analyze the T cell response occurring in 
experimental contagious agalactia and to determine the role of antigen-specific naïve 
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or memory IFN-γ positive T cell subsets activated by different vaccine formulations 
for the treatment of contagious agalactia. 
Future perspectives 
Since this work can’t exclude the involvement of other T-cell subsets producing other 
cytokines in the immunity against M. agalactiae,  and in monitoring the efficiency of 
M. agalactiae vaccines, we would like to insight this aspect, analyzing the role of 
other cytokines and their cellular sources eventually involved in the protective or 
pathogenic process. 
Preliminary reports show that antibodies directed against some proteins are, more 
than others, represented in protected sheep rather than infected (data not shown). We 
plan to delve into the role of these proteins or their epitopes, studying their direct 
effects as vaccines in the natural host of contagious agalactia. We also plan to delete 
the open reading frame responsible of the protein production from a live 
Mycoplasma strain and demonstrate the consequent variation of clinical symptoms. 
We are going to develop an anti-Mycoplasma IgM ELISA for an early detection of 
the infection in the herd. Since there is a long time span during which IgG are not 
detectable, the early identification of the pathogen in the herd would protect the other 
animals from the infection. 
Finally, to confirm which cells are responsible for protection, it would be possible to 
use a immunocompromized mouse that accept sheep bone marrow and develops 
sheep immune system. This mouse could be infected with M. agalactiae and its 
immune response could be studied without the limits dictated by the lacking of 
commercial reagents directed to sheep antigens. 
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A method to assess the expansion of antigen-speciﬁc intracellular IFN-c positive T cell subsets during the
infection will be helpful for a better understanding of mycoplasmal infections physiopathology in the
sheep. We analysed the percentage of antigen-speciﬁc lymphocytes positive for intracellular IFN-c during
the infection of sheep with Mycoplasma agalactiae by culturing peripheral blood mononuclear cells of
infected or uninfected animals with irradiatedM. agalactiae. The expansion of antigen-speciﬁc IFN-c posi-
tive lymphocytes in infected sheep was initially sustained by CD4+ T cells at day 15 after infection, when
antigen speciﬁc IgG start to be detectable, followed by CD8/IFN-c double positive cells. cd T-cells were
not expanded at any time point analysed. IFNc+ T cells disappear 60 days after infection, suggesting that
antigen speciﬁc IFNc+ T cells, mainly detected in the early phase of the disease, could be useful to under-
stand the role of cell-mediated immunity during M. agalactiae infection.
 2011 Elsevier Ltd. All rights reserved.
Mycoplasma agalactiae (MA) is a major pathogen of sheep in
many areas in the world but particularly in Mediterranean coun-
tries. It causes contagious agalactia (CA), an infectious disease pri-
marily affecting the mammary gland (Da Massa et al., 1992;
Bergonier and Poumarat, 1996). The largely chronic nature of CA
is usually explained by the capacity of mycoplasma to evade the
host immune system by changing surface structure and expressing
lipoproteins that induce cytokines modulating the immune system
(Razin et al., 1998). Changes in the inﬂammatory cell subsets due
by MA infection have previously been reported during the mam-
mary infection (Castro-Alonso et al., 2010). Based on the recent
knowledge about CA, we have proposed that the detection of intra-
cytoplasmic inﬂammatory cytokines may be useful in shedding
light on the functions of peripheral blood lymphocytes as markers
of the infection phases. In this report, we describe a method to ana-
lyse the expansion of antigen-speciﬁc IFN-c+ T lymphocytes during
the infection with MA.
Eight healthy ewes, 3–5 year old, belonging to the Comisana
dairy breed originating from a ﬂock with no history of CA, were se-
lected for our experiment. Four ewes were inoculated after daily
milking at day 0 with 1 ml PBS containing 1  106 CFU/ml of MA
(cloned strain from a recent, conﬁrmed outbreak of MA) by intra-
canalicular route in both teats. This dose produce signs of CA in
our previous experiments. The procedure was performed using a
syringe linked to small size catheter (1.67 mm size French sterile
urinary catheter) in order to reach the mammary gland sinus.
The remaining four sheep were injected with PBS alone. During
the following 2 months, all animals were monitored weekly for
clinical changes, speciﬁc antibodies production, cellular response
and pathogen excretion in the environment. Blood samples from
all the infected and healthy ewes were collected at days 0–15–
30–45–60 after infection and sera and PBMC were analysed. After
the experiment all the animals were clinically monitored until a
full remission.
The rate of expansion of CD4+, CD8+ and TCRcd+ T-lymphocytes
positive for intracellular IFN-c after in vitro exposure to irradiated
MA was analysed on peripheral blood mononuclear cells (PBMC)
from infected and healthy ewes. PBMC were separated by centrifu-
gation of sheep blood on Lympholyte solution (Cedarlane labs,
Canada) and quantiﬁed by Trypan blue dye exclusion test. Cells
were resuspended (1  106/ml) in RPMI 1640 medium plus FCS
10%, glutamine 1%, streptomycin, penicillin, gentamycin and Hepes
(EuroClone, Italy).
Ionomycin (10 ng/ml) and Phorbol Myristate Acetate (PMA)
(5 ng/ml) (Sigma–Aldrich, Italy), as positive control for intracellu-
lar IFN-c staining, medium alone, as negative control, and
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1  106 CFU/ml of irradiated (60 Gray) MA, as stimulus for antigen-
speciﬁc cells, were added to cell cultures. After an overnight in vitro
antigen exposure, 3 lM Monensin (Sigma–Aldrich, Italy) was
added to each well to avoid IFN-c release. PBMC were collected
and pooled after 48 h of culture at 37 C 5% CO2 and ﬂow-cytomet-
ric analyses were assessed. These assays were performed staining
the cells with anti surface-FITC-labelled mAbs and anti-IFN-c PE-
labelled mAb at the concentration suggested by the suppliers in
100 ll PBS/0.1% sodium azide. Surface immunoﬂuorescence was
detected by anti-CD8 (FITC-labelled, clone CC63, mouse IgG2a,
Serotec, UK), anti-cd (FITC-labelled WC1, clone 19.19, mouse
IgG1, Serotec, UK) and anti-CD4 (FITC-labelled, clone 44.38, mouse
IgG2a, Serotec, UK). After three washes, cells were ﬁxed by 1% for-
malin buffer and permeabilized by 0.01% saponin/PBS for 10 min,
washed three times and incubated with anti-IFN-c mAb PE-la-
belled (clone CC302, mouse IgG1, Serotec, U.K.) for 15 min at
4 C. After three washes, cells were collected using a FACS-CAN
cytometer (Becton Dickinson, USA) and analysed by CELL-QUEST
PRO program (Becton Dickinson, USA). We tested the presence of
anti MA-IgG in sera of infected sheep by an indirect ELISA test
(Institut Pourquier, Montpellier, France) in each infected sheep.
The corrected OD 450 nm value of the sample divided by mean cor-
rected OD 450 nm value of the positive control  100 (S/P%), sam-
ples with a S/P% equal to or lower than 50% are considered to be
negative, samples with a S/P% between 50% and 60% are considered
to be doubtful, samples with a S/P% equal to or greater than 60% are
considered to be from a sheep which has been in contact with M.
agalactiae (Poumarat et al., 2009).
The Mann–Whitney U test was used to compare statistical sig-
niﬁcance of data from infected and healthy sheep, and the value of
P < 0.05 was chosen to be signiﬁcant comparing the data obtained
from infected and control group.
All MA inoculated sheep started to show swelling, rise in tem-
perature and pain of both the udders followed by a severe decrease
in milk production in 4–5 days after infection and reduction in size
of the organs. In one case left carpal joint was affected by arthritis:
joint were swollen, warm and painful. No ocular lesions were re-
corded in this trial.
Fig. 1. Panels showed in the ﬁgure were obtained acquiring to the FACS-CAN (Becton Dickinson) 10000 events after gating lymphocytes. In infected sheep, panel of CD4+ IFN-
c+ were obtained 15 days after infection, CD8+ IFN-c+ 30 days after the infection.
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Analysis of PBMC cultured with irradiated MA antigen showed
the expansion of antigen-speciﬁc IFN-c+ T cell subsets at day 15,
30 and 45 after MA infection. Fig. 1 shows representative panels
of CD4 and CD8 positive cells from infected sheep in vitro re-ex-
posed to MA antigen and stained with intracellular anti-IFN-c.
As shown in Fig. 1A, CD4+ IFN-c+cells increase, in infected
sheep, from 0.17% to 1.91% at day 15 post infection while CD8+
IFN-c+ increase from 0.02% to 1.01% at day 30 post infection
(Fig. 1B). No expansion of double positive cells was detected in
uninfected animals (Fig. 1C and D).
Flow-cytometric analysis of PBMC from infected sheep showed
an expansion of IFN-c+ cells reaching a plateau from day 15 to day
30, compared to the non-infected ones, followed by a relevant de-
crease at day 60 (Fig. 2A). At day 15 a peak of antigen-speciﬁc
CD4+/IFN-c+ T lymphocytes expansion was detected (Fig. 2B) while
CD8+/IFN-c+ T cells had a two fold increase 30 days after infection
(Fig. 2C). From day 30, TCRcd+/IFN-c+ T lymphocytes showed no
signiﬁcant expansion (data not shown).
CD4+ cells seem to be responsible for an early cell-mediated im-
mune response, since the maximum value of CD4+-IFN-c produc-
ing cells was reached at day 15 of infection, together with, or
maybe few days before, the appearance of speciﬁc IgG. In fact, indi-
rect ELISA assays of infected sheep sera, showed the presence of
speciﬁc IgG after 15 days from the infection, with a plateau
reached 30 days after the infection (Fig. 2D).
The peak of CD4, overlapping with the increase of serum IgG,
has been described and related to an activation of the cellular
and humoral immunity (Rodríguez et al., 2000, 2001; Byrne
et al., 2005).
The role of cell-mediated immunity in mycoplasmal infections
has not been well established (Tajima et al., 1984; Razin et al.,
1998; Rodríguez et al., 2000; Sarradell et al., 2003; Byrne et al.,
2005). Differently from previous papers (Razin et al., 1998; Rodrí-
guez et al., 2000, 2001; Byrne et al., 2005), we describe an expan-
sion of MA antigen-speciﬁc CD4+ IFN-c+ T cells 15 days after
infection and an antigen-speciﬁc CD8+ IFN-c+ T cells increase at
day 30, when CD4+ IFN-c+ cells decrease. Accordingly to our data,
Castro-Alonso et al. (2010) reported that, lately, at 45 days post
infection in the breast of infected goats, the inﬂammatory process
was mainly supported by CD8+ cells. The different timing of CD8+
IFN-c+ T cells increase, reported by us in the blood of the sheep
at day 30 post infection and by Castro-Alonso in the mammary
gland of infected sheep at day 45, could be explained because, dif-
ferently from us, Castro-Alonso did not detect MA-speciﬁc CD8+
IFN-c+ T cells. Probably, in the blood the increase of CD8+ IFN-c+
T cells occurs before than in mammary glands. Our ﬁndings sup-
port the hypothesis that, after an early activation (2 weeks after
infection) of CD4/IFN-c double positive cells and a later activation
(4 weeks after infection) of CD8/IFN-c double positive cells, the
anti-MA immune response is mainly sustained by the immuno-
globulin secretion. As the total percentages of IFN-c+ cells almost
coincided with the CD4+ IFN-c+ 15 days after infection or with
CD8+ IFN-c+ 30 days after infection, NK cells seem to be a minor
component of MA-speciﬁc IFN-c+ cells.
We cannot exclude the possibility that IL-4 or other intracyto-
plasmic cytokines positivity could be involved in T cell activation
during CA.
The contribute of antigen-speciﬁc MA IFN-c+ T cells to protec-
tive immunity to CA could be a direct involvement in killing of in-
fected cells and/or MA itself, and/or these cells could play a
supporting role IFN-c mediated in the activation of B lymphocytes
and subsequent secretion of MA speciﬁc antibodies (Snapper et al.,
1988; Mohr et al., 2010). Further analyses of the immunological
features characterizing sheep infection, are needed to deeply
understand the role of IFNc+ cells expansion in the protective im-
mune response to MA.
The assessment of our antigen-speciﬁc intracellular IFN-c+ T
cells analysis could represent a new approach in monitoring im-
mune response of sheep infected with MA.
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Fig. 2. PBMC from healthy (}) and infected (j) ewes were obtained at the time points showed in the ﬁgure. The percentages of double positive cells were obtained analysing
10000 events on lymphocytes gate (Mann–Whitney U test ⁄ < 0.05). IgG from sera of infected ewes (s) were obtained at the points showed in the ﬁgure and analysed by
commercial indirect ELISA assay anti-M. agalactiae IgG. We calculated for each infected sheep the corrected OD ratio and we show the mean for each time points.
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 Abstract 22 
In the scenario of the available vaccines against Contagious Agalactia, little is known about the 23 
protection they confer and their efficacy. This paper approaches the comparison of four different 24 
vaccine formulations, in terms of pathogen spreading control and containment of clinical signs. In 25 
particular, a vaccine that reduces the load of Mycoplasma agalactiae in milk, nasal and ocular 26 
secretions could be very important to minimize the spreading of this pathogen in the herd. Here we 27 
show that some vaccines used protect with different efficacy the sheep both in terms of clinical 28 
manifestations and in terms of pathogen excretion. In spite of the limited number of animals, results 29 
show how the live attenuated vaccine, not allowed in European Union, conferred the best clinical 30 
protection, when compared to a control group, followed by saponin-treated vaccine.  31 
Keywords: Vaccines comparison, Contagious Agalactia, Mycoplasma agalactiae 32 
33 
 Introduction 34 
Contagious agalactia (CA) is a major veterinary problem of many countries involved in small 35 
ruminants farming. This disease affects small ruminants livestock causing a severe mastitis, arthritis 36 
and keratoconjunctivitis. Mycoplasma agalactiae is the most common causative agent, a wall-less 37 
bacterium belonging to Mollicutes, characterized by high virulence and contagiousness. 38 
 39 
Different vaccines have been produced in Italy (Tola et al., 1999)they are made by Istituti 40 
Zooprofilattici Sperimentali and are veterinary products prepared from wild strains directly isolated 41 
from the outbreak. These are usually utilized under veterinary prescription to immunize the 42 
remaining healthy heads kept in the farm. 43 
 44 
In the last decade immunogenic proteins of M. agalactiae have been identified as suitable for 45 
vaccines against the disease (Tola et al., 1999) but their practical development to become a vaccine 46 
has been actually improbable. Many authors don’t recommend single proteins as potential 47 
protective vaccine, also due to antigenic variation of the pathogen (Bergonier  et al., 1996; de la Fe 48 
et al., 2006). Nevertheless the real efficacy of currently circulating products (inactivated 49 
monovalent vaccines) is still doubtful in field conditions (de la Fe et al., 2007). 50 
 51 
Nowadays, control of CA is mainly based on the application of veterinary regulations. In Europe 52 
some different inactivated vaccines are available, but live attenuated vaccines are not acceptable, in 53 
spite of positive clinical feedback from countries where it is currently utilised (Turkey) (OIE 54 
manual, 2008). Unfortunately, with the exception of few drugs as tylosin and new fluoroquinolones 55 
that were demonstrated to have a good in vitro Minimal Inhibitory Concentration (Loria et al., 56 
 2003), antibiotics are poorly effective against M. agalactiae. Vaccination could massively reduce 57 
the cost of treatment when used as preventive tool. 58 
 59 
The efficacy of vaccine against CA have been reported for some inactivated product (Tola et a1., 60 
1999; Buonavoglia et al., 2008; Consenti et al., 1999), showing data on clinical efficacy (udder 61 
changes, milk changes, fever, general body conditions, arthritis, conjunctivitis, etc.) among different 62 
products. No data have been reported on effectiveness of vaccines in terms of reduction of excretion 63 
of the pathogen in the environment. Analogously no information has been collected on 64 
environmental impact following the use of the vaccine, especially when, in order to protect the 65 
remaining healthy milking sheep, farmers treat the whole group. 66 
 67 
The aim of the study is to investigate current vaccines available against the disease, including 68 
either inactivated vaccine or attenuated products. Inactivated vaccines allowed in EU, concern 69 
commercial products and farm vaccines. They are based on similar procedures of antigen 70 
production and inactivation, but the commercial ones can utilize only an officially registered strain, 71 
whereas farm vaccine are prepared with the wild strain isolated in the outbreak. 72 
 73 
This is the first report aimed to determine the efficacy of different vaccine formulations in the 74 
treatment of CA. The purpose of this work is to provide evidence of the effectiveness of vaccines 75 
and the protection that they are able to confer, giving information for veterinary management in 76 
course of infection. A comparison of different vaccines formulations was thus performed, evaluating 77 
those that in our opinion are good indicators, together with immune parameters that we’re 78 
analysing, of vaccine effectiveness: clinical symptoms and pathogen excretion. 79 
  80 
Materials and methods 81 
Experimental design 82 
Twenty-seven adult lactating sheep were selected from a dairy herd microbiologically and 83 
serologically negative for M. agalactiae, other mycoplasmas or other mastitis etiological agents. All 84 
ewes belonged to the same breed (Comisana) and were aged between 2 and 4 years. All animals 85 
were subjected to synchronisation of their estrum. After parturition, a proper weakening interval of 86 
time was additionally considered in order to feed new-born lambs with colostrum. After this period, 87 
27 sheep were ready and synchronized for milking season. Twenty-five of them were divided in five 88 
groups of 5 ewes each, while 2 were chosen (but excluded from data analysis) as inoculated “in 89 
contact” animals for later challenge (Tola et al., 1999; de la Fe et al., 2007). Four groups were 90 
inoculated with a first dose of vaccine, following manufacturer instructions. The fifth group was not 91 
vaccinated and was considered as control. Four weeks after the first vaccination, all the groups 92 
treated with inactivated products were boosted with an identical dose of vaccine whereas attenuated 93 
vaccine was administered once only. The two remaining animals were used as source of infection 94 
by inoculation via intracanalicular route of live Mycoplasma agalactiae wild strain. These 95 
“challenge” sheep were infected and joint to the flock few days post booster vaccination. Once 96 
vaccination protocols were completed, all ewes were thus farmed and milked together as one flock, 97 
in order to get the same chance to be exposed to the pathogen, resembling natural infection. All the 98 
animals were monitored once a week for 26 weeks. Milk, blood and swabs samples were collected 99 
weekly from all ewes; all the data were then statistically analysed. Infected animals were than 100 
pharmacologically treated to induce drying off and complete recovery. 101 
 102 
Vaccines 103 
 Performances of four different vaccines (Tab. 1) have been studied. The farm vaccine used was 104 
formalin inactivated with Quil A as adjuvant (hereafter “farm” vaccine). Another vaccine, 105 
commercially available, is formol-treated and contains Aluminium hydroxide as adjuvant. It was 106 
bought from a local veterinary pharmacy (hereafter “commercial” vaccine). Alive vaccine was 107 
kindly supplied by a Turkish Institute (hereafter “live” vaccine) and a novel saponin-inactivated 108 
vaccine, in which saponin acts as inactivant and adjuvant in the same time (hereafter “saponin” 109 
vaccine) was also provided by the producing pharmaceutical company and used. 110 
 111 
Challenge 112 
The field strain used for inoculum preparation was isolated from a Sicilian outbreak of CA, and 113 
then confirmed by biochemical and PCR analysis. After isolation the strain was cultured in 114 
modified Hayflick broth (500 ml) (Nicholas et al., 2009), after 72 hours incubation at 37°C, the 115 
culture was harvested at 10.000g for 30 min and re-suspended in the same volume of phosphate 116 
buffered saline (PBS) solution, pH 7.2. M. agalactiae antigen suspension was further stored in 117 
1.5ml criovials and frozen at -80°C, when necessary. Viable M. Agalactiae antigen was quantified 118 
before inoculation by the method described by Postgate (Postgate, 1969). 119 
 120 
A 1.5 ml-inoculum containing 10
5
 CFU of M. agalactiae was injected intracisternally into both 121 
halves of the mammary glands of 2 sheep belonging the group of non-vaccinated ewes. Animals 122 
were kept together and milked daily two times per day (7.00 AM and 4.00 PM) before and after 123 
grazing, as traditionally performed in Sicily. After milking the infected ewes, the operator would dip 124 
his hands in the infected milk and milk the vaccinated and control sheep, in order to resemble 125 
natural infection (Tola et al., 1999; de la Fe et al., 2007). 126 
 127 
 Ethics 128 
The experiment was carried out in accordance with the Code of Practice for Housing and Care of 129 
Animal used in Scientific Procedures (EU Directive 2010/63/EU). The work was reliable using the 130 
animal facility of Istituto Zootecnico Sperimentale per la Sicilia (Palermo), where lactating sheep 131 
were managed according to traditional production management. The experiments were carried out 132 
with the authorization of the Italian Ministry of health (Decreto Ministeriale N° 101/2006 –A).  133 
 134 
Clinical assessment 135 
All sheep were clinically monitored in order to determine pathologic changes in the udder. 136 
Udders and milk were evaluated once a week, during milking procedure with a simple score (Yes-137 
No) enrolling those symptomatic as mastitic sheep. Clinical data (presence of mastitis, arthritis, 138 
conjunctivitis) were recorded till the complete recovery of the sheep that was correspondent to week 139 
26 after challenge. 140 
 141 
Mycoplasma cultures and PCR 142 
Milk samples (300μl) or nasal and ocular swabs, were cultured both in solid agar plates and 143 
liquid medium. Purification of the organism by further cloning sub-cultures was always essential 144 
before identification (Nicholas and Baker, 1998). The samples were additionally cultivated on 5% 145 
sheep blood agar (Merck, Darmstadt, Germany) at 37°C under both aerobic and anaerobic 146 
conditions, as well as on Tryptic Soy Agar (DIFCO Laboratories, Detroit, Michigan, USA) in order 147 
to monitor eventual other bacterial infections. Isolates were then analysed using standard 148 
biochemical tests (Poveda et al., 1998) and molecular biology method (16S rRNA gene PCR) as 149 
described previously (McAuliffe et al., 2003; McAuliffe et al., 2005). 150 
  151 
The surface drop method of Postgate (Postgate, 1969) for the determination of viable cells in 152 
milk sampleswas adopted. The 95% confidence limit of the number of the colonies counted (x) 153 
was calculated as approximately x  1.96 x (Meynell and Meynell, 1970). 154 
 155 
Statistical analysis 156 
The data of M. Agalactiae excretion in milk, ocular and nasal swabs were analysed considering 157 
the mean of CFU ± SD obtained by the determination of viable cells from the collected samples. 158 
The data were analysed with a statistical model of analysis of variance ANOVA. A risk analysis was 159 
also calculated separately analysing the probability for the animal to suffer of clinical symptoms, 160 
and the spreading of the pathogen in the environment (ocular and nasal swabs). These values were 161 
obtained using the Relative Risk and their I.C. 95%. Antibodies optical density were analysed with 162 
a statistical model of analysis of variance ANOVA for repeated measures. The confidence value was 163 
fixed at 0.05. The analyses were performed using Statistica 5.0 (StatSoft, Inc., 2010) and Openepi 164 
(Dean et al., 2011) software. 165 
 166 
Results 167 
Live and saponin vaccine conferred the best protection against clinical symptoms 168 
Clinical data were recorded weekly, till the week 26 after challenge, period when complete clinical 169 
recovery was observed in all vaccinated ewes still enrolled at the end of the study. The two 170 
intramammary inoculated animals, utilised for the challenge, showed mastitis few days post 171 
infection, but they were excluded from data collection. In the Fig.1 is shown the mean percentage of 172 
symptomatic animals during the whole observation period. Control group showed a typical 173 
behaviour of natural infection, characterised by high morbidity and sub-acute course of the disease 174 
 (Stazzi and Mirri, 1986). The groups of “in contact” vaccinated sheep showed clinical signs of CA 175 
after the second week post challenge with highest incidence of mastitis 4 wpi (weeks post 176 
infection). At this time point a total of 10 sheep showed CA symptoms and 9 sheep were severely 177 
affected: 4belonging to control group, 4 to the commercial vaccine group and 1 to the farm vaccine 178 
group (Tab 2). In the first stage the disease was visible as mild unilateral or bilateral mastitis with 179 
warm, swollen, painful parenchyma, later followed by sclerosis and typical reduction in size of one 180 
or both the organs. Mammary lymph-node was always involved showing from mild to marked 181 
enlargement in size. The presence in the udder of one of the above-mentioned changes was 182 
considered as “mastitis”. Two ewes only (8% of the total number) showed arthritis (1 ewe 183 
belonging to saponin inactivated vaccine group) and monolateral conjunctivitis (1 sheep belonging 184 
to control group). Arthritis involved all limbs, particularly visible in carpal and tarsal joints. 185 
 186 
Vaccinated groups were then analysed in terms of relative risk to be affected by symptoms of 187 
CA, giving the value of control group equal to 1, which represents the certainty to suffer of mastitis, 188 
arthritis and/or conjunctivitis. The relative risk to be affected by mastitis, conjunctivitis and/or 189 
arthritis was thus calculated, considering more effective a vaccine able to protect by clinical 190 
symptoms. From this point of view the range of efficacy of vaccines resulted to be: 191 
LIVE (0,12) > SAPONIN (0,24) >FARM (0,4) > COMMERCIAL (0,96) 192 
The limited number of units per group (5) is not statistically significant; nevertheless the 193 
statistical analysis gave an interesting model about the different behaviour of the groups treated 194 
with the different vaccine formulations. The value of 0.12 obtained by the analysis of Live vaccine 195 
group means a protection of about 88% to develop clinical signs of CA. Among inactivated 196 
vaccines the best results in terms of clinical protection was recorded in saponin-vaccinated group, 197 
followed by farm vaccine. On the contrary, a value of protection near to zero was unexpectedly 198 
 found in the commercial vaccine. For humanitarian reasons, between the 12
nd
 and the 13
th
 wpi, 199 
three sheep from control group and other 4 from the commercial vaccine group, were 200 
pharmacologically treated and excluded from the experiment, because of severity of symptoms. At 201 
26 wpi (experiment conclusion), complete clinical recovery was observed in all the ewes. 202 
 203 
Microorganism excretion as a parameter of vaccine efficiency 204 
The behaviour of the different vaccines in terms of reduction of pathogen excretion in milk was 205 
also monitored: all the groups secreted the bacteria through the milk since the first wpi, but each 206 
group showed a different behaviour regarding the excretion of the pathogen in the milk. The highest 207 
number of Mycoplasma-secreting sheep was recorded in the first week, when the most of animals 208 
were asymptomatic. However, the peak of the microorganism excretion in terms of CFU/ml values 209 
was reached around the 4
th
 wpi. The peak of Mycoplasma excretion in each group showed different 210 
trends: at week 2 in the live vaccine-treated group, at week 3 in the control group, at week 4 for 211 
saponin vaccine and at week 5 for the commercial vaccine and farm groups. In spite of the 212 
encouraging clinical trend, residual excretion (one head per group) was still recorded in Control and 213 
farm groups at the end of the study (26
th
 week). Live and saponin inactivated treated groups showed 214 
complete clearance of the pathogen after 22 and 19 weeks respectively. The pathogen excretion in 215 
the milk, measured by CFU, was also analysed with the ANOVA test in order to know if the 216 
differences among groups were statistically significant. It was rejected the null hypothesis since p 217 
was calculated to be 0.023, assuming a significant value equal to 0.05 (data not shown).The 218 
variation of pathogen excretion with respect to the vaccine used, and the relative standard 219 
deviations, during the whole period of observation, is shown in Fig. 2. Commercial vaccine cause 220 
an increase of 94.57% of excretion of the pathogen through the milk, while farm vaccine allows a 221 
contraction of the pathogen spreading of 29.75%, together with saponin and live vaccines, which 222 
allow a reduction of M. agalactiae excretion of 75.02% and 74.65%, respectively. It can be noted 223 
 how the vaccines able to protect from clinical symptoms are also able to limit the spreading of 224 
bacteria in the environment. 225 
 226 
By the comparison at week four (period considered as “at maximum risk” of exposure) of all 227 
vaccinated sheep with control animals, the Fisher exact test applied on milk, ocular and nasal swab 228 
cultures, demonstrated that the risk ratio between non vaccinated and vaccinated animals resulted in 229 
most cases <1. The values are showed in Table 3. These data underline the importance of the 230 
vaccines in conferring protection not only to the single animal, but also to the whole herd. Fig. 3 231 
summarizes clinical performances and excretion data in milk for all groups. The reported trends 232 
underline, at selected weeks throughout the experiment, the difference between clinical behaviour 233 
and antigen elimination in the flock. In control as well as in animals treated with Commercial 234 
vaccine there are higher incidence of clinical symptoms at 4 and 8 wpi, when compared to the 235 
incidence values detected in groups treated with farm, saponin and live vaccines. Saponin and live 236 
vaccines are able to decrease from the 4
th
 wpi on the amount of M. agalactiae secreting sheep. No 237 
reduction of M. agalactiae secreting sheep was detected at 4 wpi in farm vaccine treated animals 238 
while after 8 wpi a drastic reduction of this value was observed in this group. 239 
 240 
Discussion 241 
The present study, for the first time, compared some vaccines currently available against CA 242 
suggesting more correct veterinary choice in case of outbreak. The prolonged monitoring of antigen 243 
excretion in the environment in control and vaccinated animals is one of the tools to determine the 244 
risk of spreading infection and, as a consequence, the effectiveness of a vaccine. The data regarding 245 
the pathogen excretion in conjunctiva, nasal mucosa and milk were thus analysed in order to 246 
determine the role of the vaccines in conferring protection to the vaccinated animal. The differences 247 
 of pathogen excretion through the milk resulted to be statistically significant among groups, and 248 
each group showed different ability to spread the pathogen in the environment. 249 
 250 
Vaccinated animals showed a significant reduction of the pathogen elimination in the 251 
environment, when compared to the non-vaccinated, strengthening the importance of vaccines in 252 
controlling the disease either in the farm or in the area. The results showed a significant decrease in 253 
relative risk of elimination of the bacteria through the milk and nasal mucosa. The variation of the 254 
excretion of the pathogen by ocular fluids between the two groups was not significant, but in our 255 
experience the role of the transmission of the disease by this route should be considered less 256 
relevant. 257 
 258 
The sheep belonging to the live and saponin vaccinated groups eliminated significantly less 259 
bacteria in the environment in comparison with commercial product treated group, thus reducing the 260 
incidence of infection in the herd. This phenomenon has a huge impact in the improving of 261 
economic management related to the milk products. 262 
 263 
Similar results were obtained considering the incidence of clinical symptoms: live-attenuated 264 
vaccine was able to confer to the entire group a good clinical protection, and none of them showed 265 
typical CA symptoms. Saponin and farm vaccines conferred a similar degree of protection, and only 266 
one animal per group showed clinical symptoms. Eighty per cent of animals belonging to 267 
commercial-vaccine group showed severe clinical symptoms. 268 
 269 
 The whole data analysis suggests that the live attenuated vaccine was the most effective one. 270 
Among the inactivated vaccines, the saponin inactivated formulation resulted to be the most 271 
effective, followed by the farm vaccine that had a weaker protective effect in terms of pathogen 272 
excretion in the milk as well as of number of M. agalactiae secreting sheep. Basing on the data 273 
collected by this study, a more relevant role should be ascribed to vaccination against CA utilizing 274 
the vaccines that resulted protective by our analysis (live, saponin and farm). These vaccinated 275 
groups show better health conditions, milk production and protection against the clinical symptoms 276 
when compared with control and commercial vaccine groups. Among inactivated vaccine 277 
formulations, hereby tested, the vaccine inactivated with saponin resulted to be the most effective, 278 
but live attenuated vaccine conferred an excellent protection in all the animals tested. 279 
 280 
It can be hypothesized that the different protective effects of vaccine formulations depends on 281 
their intrinsic features. Commercial product is less protective than other vaccines probably because 282 
of the strain used. The strain, in fact, has to be registered and it is possible a gradual loss of 283 
immunogenic activity due to the antigenic variability of M. agalactiae strains. In other words the M. 284 
agalactiae strain used to prepare commercial vaccine could display many antigenic differences with 285 
M. agalactiae strain used to infect the sheep in this work. As above mentioned, live vaccine is an 286 
attenuated strain cultured in chicken eggs. As live vaccine, it can take advantage of the natural 287 
amplification of antigenic load consequent to bacteria proliferation. To the best of our knowledge, 288 
the saponin used in both farm and Saponin vaccine, should act through the same mechanism for the 289 
stimulation of the host immune response. Unfortunately, the exact composition of Saponin vaccine 290 
is not known (because of commercial rules), thus the reason why farm vaccine is less effective than 291 
Saponin vaccine cannot be completely defined. The difference could be due to the antigen damage 292 
caused by formalin, whereas saponin inactivation effect is mainly based on disruption of 293 
mycoplasma membranes without denaturating immunogenic proteins (Bangham et al., 1962). 294 
  295 
This is the first evidence of the different efficacy of vaccine formulations in the control of CA in 296 
terms of pathogen excretion and its potential environmental impact. Furthermore vaccine utilization 297 
may reduce the risk of residues of antibiotics in dairy products for human consumption. 298 
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 Table 1 376 
Overview of the vaccine formulations used in this experiment 377 
Group 
name 
Vaccine  
 
Numbe
r of 
animals 
Producer  Inactivation 
procedure 
Adjuvants  
Live Live attenuated 5 Turkish Veterinary 
Institute 
100  repeated 
passages 
in eggs  
 
--- 
Saponin Saponin vaccine  5 Pharmaceutical company 
1  
2 mg/ml 
saponin 
 
--- 
Farm Farm vaccine  5 Italian Veterinary 
Institute 
0.4% formalin 200µl/ml  Quil 
A 
Commercial Commercial  5 Pharmaceutical company 
2 
0.2% formalin Aluminium 
hydroxide 
Control None 5 --- --- --- 
 378 
Animals were vaccinated with a proper dose of vaccines, following manufacturer instructions, and 379 
boosted after 30 days. Control group was not subjected to any vaccine injection. 380 
381 
 Table 2 382 
Percentages of sick animals in each group 4 weeks after infection 383 
Group Number of 
Animals per 
group 
% of sick animals 
Live 5 0 
Saponin 5 20 
Farm 5 20 
Control 5 80 
Commercial 5 80 
 384 
In control and commercial vaccines groups 4 sheep out of five presented classical CA symptoms 385 
(mainly mastitis, only one ewe in control group showed mastitis and arthritis). In saponin vaccine 386 
group one sheep presented joints constraint, in Farm vaccine group a ewe was mastitic. In Live 387 
vaccine group, no ewes showed CA symptoms 388 
 389 
390 
 Table 3 391 
Risk values in vaccinated and non-vaccinated sheep 392 
 
Risk value in  
non-vaccinated 
group (%) 
Risk value in 
vaccinated groups 
(mean) (%) 
Ratio 
Nasal swab 23.53 50 0.47 
Ocular swab 8.33 7.14 1.167 
Milk excretion 29.41 83.33 0.35 
 393 
The table compares the risk values to take contact with the pathogen between vaccinated and non-394 
vaccinated animals. The Fisher exact test demonstrates how important is the vaccination to limit the 395 
risk to be affected by CA by pathogen excreted through nasal mucosa and milk. 396 
397 
 Figure legends 398 
 399 
Fig. 1. Incidence of clinical symptoms. The percentage of CA symptoms as an average of clinical 400 
manifestations during the whole monitoring period is shown. All the classical clinical symptoms 401 
were considered: mastitis, conjunctivitis and arthritis. The animals out of experiment were still 402 
considered symptomatic. 403 
 404 
Fig. 2. Modification in excretion of M. agalactiae in the milk in vaccinated animals compared to 405 
Control group. The figure shows the mean values of pathogen excretion during the whole period of 406 
observation per each group compared to control group. The value of CFU/ml in the milk sample of 407 
control group was considered as “zero” and the percentages with respect to this group together with 408 
the relative standard deviations, were calculated. Positive values represent an increase of excretion 409 
of the pathogen while negative values mean a contraction of the pathogen spreading.  410 
 411 
Fig. 3. Comparison of trends of clinical symptoms and milk excretion among groups at different 412 
time points. Data were analysed in order to compare the clinical behaviour and the pathogen 413 
spreading of the different groups 1, 4 and 8 wpi. In the first week after infection, all animals were 414 
still asymptomatic, but they were already secreting Mycoplasma by milk. Four wpi, it was recorded 415 
the higher number of symptomatic animals when compared to the other time points, mainly due to 416 
the contribution of control and commercial vaccine-treated animals. At the same time, there was the 417 
higher amount, in terms of CFU/ml of Mycoplasma excretion in the milk (see text). After 8 weeks 418 
post challenge, some ewe stopped to produce milk because of mastitis, and they were no longer 419 
considered «secreting» but still symptomatic (data not shown). 420 
 421 
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Abstract  
Background 
Mycoplasma agalactiae is a major pathogen of sheep in many areas of the world and particularly in 
Mediterranean countries. It causes Contagious Agalactia, an infectious disease primarily affecting 
mammary glands. Many vaccines are currently under revising with the aim to protect the animals 
from the disease. The aim of the study is to investigate the involvement of T cell-mediated 
immunity in protection and pathogenic mechanism of Contagious Agalactia. A comparison of the 
antigen-specific Interferon gamma positive T cell memory and naïve subsets was performed 
between vaccinated and non vaccinated sheep to identify cellular correlates of protection and/or 
disease. 
Results 
Data reported in this manuscript demonstrated that two out of the three vaccines used in this study 
protected sheep from the disease; in the protected groups memory CD4+ Interferon-γ+ T cells 
underwent an early expansion (p<0.05 when compared to unprotected groups), whilst memory 
CD8+ Interferon-γ+ T cells have increased in non-protected animals since 7 days post infection 
(p<0.05). γδ+ Interferon-γ+ T cells reached peaks of expansion in infected and in two vaccinated 
groups indicating that these cells aren’t preferentially involved in protection or pathology (p<0.05). 
Conclusions 
Hereby we propose that the early activation of memory CD4+ Interferon-γ+ T cells, rather than 
CD8+ or γδ+ Interferon-γ+ cells should be considered as a marker of protection from the disease as 
well as a tool to establish vaccine efficacy. 
Keywords: Mycoplasma agalactiae, cellular immunity, IFN-γ+ cells 
 - 3 - 
 
Background  
Mycoplasma agalactiae is the major pathogen cause of Contagious Agalactia (CA), a severe 
syndrome of small ruminants characterized by mastitis, arthritis and keratoconjunctivitis [1]. The 
disease is a real priority in Mediterranean livestock and it is included in the list of notifiable 
diseases issued by the OIE (World Organization for Animal Health) because of its economic impact 
and widespread distribution [2].  
Little is known about the immunity acquired during infection and/or vaccination against M. 
agalactiae [3-5], and the expansion of T cells subsets under specific stimulation in vitro has been 
never investigated [6]. 
In Italy available vaccines are commercial M. agalactiae inactivated products (formalin or saponin 
inactivated) and autologous products (so called “farm vaccine”) supplied by Italian Experimental 
Zooprophylactic Institutes (IZSs) limited in their use where outbreak is officially notified in the 
infected farm. Some vaccine formulations (saponin or ethanol inactivated vaccines) seem to be 
more effective than others [2]. However, a live attenuated vaccine, not yet allowed in EU, has been 
used in Turkey since the ‘30s, with good clinical results. As a consequence, no standard vaccine 
against CA has been universally utilized and, in spite of its severe economic losses [7, 8], control of 
CA in endemic areas is still a controversial issue [6]. 
The antigenic variation of M. agalactiae surface antigens [9-11] could reasonably be one of the 
causes of the loss of efficacy of host immune response, but there is still lack of information 
regarding the immune response itself elicited by M. agalactiae and related lymphocyte subsets and 
cytokines involved [3-5]. 
The aim of this study is to investigate the involvement of T cell subsets in sheep treated with 
different vaccine formulations followed by an experimental challenge with M. agalactiae, in order 
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to find a correlate of protection suitable to be used as a marker of the efficacy of the host immune 
response and/or of the protection conferred by the vaccine. 
Results  
Two vaccines protect sheep from contagious agalactia 
The previously selected ewes were vaccinated, infected and monitored as described in Fig. 1A. The 
time points to analyse were chosen in order to investigate memory cells involvement useful to 
define a protection induced by a vaccine. Control group wasn't inoculated with any vaccine. 
Intracanalicular infected ewes showed classical symptoms of CA five days post infection. The 
presence of M. agalactiae infection was confirmed microbiologically from milk and swabs 
collected from these animals. M. agalactiae was isolated from each inoculated sheep. These animals 
act as a good source of infection for the other ewes, and the presence of M. agalactiae in all 
secreting sheep was confirmed both by specific PCR and by cultural techniques. 
The percentages of symptomatic sheep in infected and/or vaccinated groups during the period of 
observation are showed in Fig 1B. The clinical and immunological data were collected from day 0 
to day 90 after infection. Clinical signs of CA in the naturally infected and vaccinated animals arose 
only after the second week post challenge. 
The highest value of prevalence of mastitis was recorded four weeks after challenge. A total of 9 
sheep were affected by mastitis: 4 sheep belonging to group 1 (infected control group), 4 belonging 
to group 4 (sheep treated with Commercial vaccine), 1 belonging to group 2 (farm vaccine) and 
none belonging to group 3 (saponin vaccine). Only two ewes of the total amount of treated sheep 
(8%) showed other CA symptoms: one was affected by arthritis (group 3) and one by monolateral 
conjunctivitis (control group) that overlapped with classical mastitis.  
From the data recorded, it was possible to conclude that the vaccine better involved in protection 
from clinical symptoms is the saponin vaccine, followed by farm vaccine. Commercial vaccine was 
not able to confer protection in the 80% of the group. 
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Immunoglobulin presence doesn’t relate to protection 
The specific anti-Mycoplasma agalactiae antibodies trend was evaluated in order to determine if 
there was a significant difference among groups in the time-span of 26 weeks. The presence of 
immunoglobulin was thus monitored with a qualitative ELISA since one week before vaccination. 
The day before the infection, after the two doses of vaccines, about 75% of vaccinated sheep 
resulted positive for anti-Mycoplasma IgG. In the control group, anti-Mycoplasma specific IgG 
have not been detectable until 4 weeks after challenge. Time of detection of antigen-specific IgG in 
our model is consistent with those found in other reports [17, 18]. The statistical analysis confirmed 
as significant the variation of OD values in the groups in the time course, but not relevant the 
differences among groups (data not shown). 
CD4+- CD45R0+- IFN-γ+ T-lymphocytes increased in the early phase of immune response in 
protected animals 
The T cell subsets monitoring was assessed comparing the vaccinated groups with natural-like 
infected group, in terms of in vitro expansion of cellular subsets specifically activated by an 
irradiated M. agalactiae, and IFN-γ was considered as a marker of cellular activation, as previously 
published [3, 19]. The data related to the cellular subsets of CD4+CD45R0+- CD4+CD45RA+- 
CD8+CD45R0+- and CD8+CD45RA+- and γδ+ T-lymphocytes were obtained collecting PBMC at 
days 0, 7, 15, 30 and 90 after infection and culturing the cells for 48 hours with the specific 
irradiated antigen. The cellular trend was analysed indicating the percentage of antigen-specific 
IFN-+ cells, distinguishing between CD4+ (CD45R0+ or CD45RA+) and CD8+ (CD45R0+ or 
CD45RA+) and γδ+ cells. 
Data showed in figure 2A describe the relative percentages of CD45R0/CD45RA in gated CD4+ 
IFN-γ+ cells in each group at different time points. Animals treated with vaccines used in the group 
3 and 2 show a mild cellular expansion at day 7, followed by a more relevant expansion of 
CD4+CD45R0+ IFN-γ+ at day 30 in the group 3, and 15 dpi in the group 2, maintaining high 
percentages of memory cells at day 90 after infection in both groups. 
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In the group 4, this subset shows a mild expansion not earlier than day 15, reaching and maintaining 
a plateau until the day 90 after the infection. 
In the control group there is a slight increase of the value of antigen-specific CD4+- CD45R0+- IFN-
γ
+
 T-lymphocytes, reaching a plateau from day 30 on, even if the percentages reached a value 
significantly lower than those of the same time points of clinically protective vaccine groups. 
The level of CD4+- CD45RA+- IFN-γ+ T-lymphocytes does not show a significant increase in the 
group 2 but until day 15 high percentages of naïve CD4 T cells are detected. On the contrary, 
control and Commercial vaccine treated groups show higher percentages of naïve CD4 cells 7 dpi, 
when compared to the same time points of protected groups. 
Figure 2B describe the absolute percentages of CD4 memory cells in the time points analysed to 
show the levels of CD4+CD45R0+ IFN-γ+ cells during the time of observation. Data obtained from 
animals of groups 1 and 4 don’t reveal any significant modifications of the absolute percentage of 
the memory subset in all time points studied. The expansion of CD4 memory IFN-γ+ in the group 2 
becomes significant only from day 30 post infection (p<0.05). Maximal absolute percentages of 
CD4+CD45R0+ IFN-γ+ cells were observed 30 and 90 dpi in the group 3 (p<0.05).  
CD8+ CD45R0+ IFN-γ+ T-lymphocytes increase in sick animals 
Figure 3A shows the relative percentages of CD45R0/CD45RA in gated CD8+ IFN-γ+ cells. In the 
group 1 high percentages of CD8 memory cells from day 15 to day 90 have been detected. CD8+ 
CD45R0+ IFN-γ+ T-lymphocytes increase from day 0 to day 30 in the group 4. In the group 3, two 
peaks of CD8+ memory IFN-γ+ cells were observed at days 15 and 90. The higher percentages of 
CD8+ CD45R0+ IFN-γ+ T cells were observed in the group 2 in two time points of immunological 
monitoring: one occurs at day 7 and the other reach a plateau from day 30 to day 90.  
Figure 3B shows the absolute percentages of CD8 memory cells during the observation period. 
Cells from animals of Group 1 increase significantly, when compared to protected group 3, from 
day 15 to day 90. In the unprotected group 4 CD8+ CD45R0+ IFN-γ+ cells increase only at day 30 in 
absolute percentages. 
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γδ
+
 IFN-γ+ T lymphocytes quickly expand in a vaccinated and unprotected group 
In the group 4 no significant expansion of γδ+ IFN-γ+ T lymphocytes was detected during all the 
time points of observation (Fig 4). The trend of γδ+ IFN-γ+ T lymphocytes shows an early 
statistically significant expansion at day 7 in the control group (p<0.05), followed by a new 
expansion 30 dpi when compared to the same time points of group 3. They reach again lower levels 
at day 90. γδ+ IFN-γ+ T lymphocytes raised in the group 2 30 dpi (p<0.05). A relevant peak of this 
cellular subset was also detected in the group 3 at day 15 after infection. 
Discussion  
The study of the antigen-specific cellular subsets activated in response to M. agalactiae, was aimed 
to the deepening in the protective mechanisms conferred by the different vaccine formulations to 
the natural host of CA. Even if the data reported concern a limited number of animals, they 
represent a step ahead in the knowledge of small ruminants Mycoplasma infections. 
The attention was focused both in the memory cell populations (CD45R0+– T lymphocytes), whose 
timing of expansion was considered a consequence of the efficiency of vaccination, and in the naïve 
cell populations (CD45RA+ – T lymphocytes) that could be considered the reservoir of memory 
cells [20]. It is well known that upon stimulation by specific antigen, naive T cells lose CD45RA, 
acquire CD45R0 antigen and are finally recruited into the peripheral pool of memory T cells. [21, 
22]. 
Even if the cytokine IFN-γ was used as a marker of the activation state in other Mycoplasma models 
of infection [19, 23], it should not be considered exhaustive of the cytokines scenario that indeed 
could be involved under the stimulus of the M. agalactiae infection. However, antigen-specific 
IFN-γ+ T cell subsets could be useful to monitor the T-cell mediated immune response during the 
infection. The T cell response of  IFN-γ+ lymphocytes to M. agalactiae infection detected in the 
control group during this experiment confirmed our previous results describing, in infected sheep, a 
first increase of CD4+ IFN-γ+ cells followed by an expansion of CD8+ IFN-γ+ lymphocytes after 
short in vitro re-exposure to irradiated M. agalactiae [3] (data not shown). The same method, 
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improved with the detection of CD45R0 or CD45RA, could give an idea of the instauration of 
immunological memory. Since in other systems memory cells are involved in an effective immune 
response induced by a vaccination [17], the contribution of this population could be considered a 
goal for a good vaccine. 
The results have emphasized how in the group treated with the effective vaccines (saponin and 
farm), the most represented T cell subset is CD4+ CD45R0+ IFN-γ+, able to increase since day 7 
after infection to day 90. The early increase of CD4+ CD45R0+ IFN-γ+ is not traceable in the control 
group and in the group treated with the commercial vaccine. We thought that the timing of 
expansion of this subset could be considered as a correlate of protection. In control group and in the 
group 4, its activation undergoes a consistent delay, which can be the cause, together with the 
expansion of CD8+ CD45R0+ IFN-γ+ T-lymphocytes, of the bad clinical conditions of animals. It 
would be interesting to perform a deeper analyses in order to classify memory cells in effector 
memory, central memory or Terminal Effector Memory RA and understand their different timing of 
activation, as showed in other systems [24], but unfortunately such reagents are not commercially 
available for small ruminants. Another explanation for the different time point when CD4+ memory 
T cells reach the maximum of expansion could be a delay in the antigen presentation in Commercial 
vaccine when compared to saponin vaccine. In all cases, CD4+ CD45R0+ IFN-γ+ T cells are a well-
known correlate of protection, as suggested by other models of infective diseases in humans [25] 
and in bovine. In order to assess an effective subunit vaccine against Mycoplasma mycoides subsp. 
mycoides, researchers are studying molecules able to activate CD4 central and effector memory 
cells, since it seems they are the most suitable peptides to be included in such vaccines [26, 27]. 
In the group that is not protected by vaccine, the infection causes an increase of the CD8+CD45R0+ 
IFN-γ+ T-lymphocytes at day 30 after infection. This group suffered of a sort of delay in cellular 
response, due to the absence of any previous contact with the pathogen (both natural or by 
vaccination). The unavailability of data around the day 60 after infection does not allow confirming 
or excluding the expansion, also in this group, of a memory subset effective in the protection 
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against Mycoplasma. An analogous trend could have been happened in the group treated with the 
Commercial vaccine, where until the day 30 after infection any effective protection against the 
pathology is detected. In this case, the strain wouldn’t be able to stimulate any cellular immune 
response, with respect to the wild type strains that are circulating nowadays. 
It would be interesting the study of the whole cytokine pattern production in the context of the 
natural infection, in order to determine if, together with the presence of CD4+CD45R0+ IFN-γ+ T-
lymphocytes, the absence of clinical symptoms can be related with other cytokine patterns (Th-2, 
Th-17, Th-9, Th-22 subsets etc.) rather than Th-1. 
Other Mycoplasma infection models in bovine suggested that the microorganism could support the 
expansion of γδ IFN-γ+ T cells releasing mevalonate metabolites [28]. In control animals (group 1) 
two peaks of γδ IFN-γ+ T cells were recorded, 7 dpi and 30 dpi. As γδ T cells are responsible of 
early innate immune response by recognition of non peptidic ligands, it could be argued that in 
control group, during the first days of infection, M. agalactiae could release non peptidic ligands 
that stimulate T cells with γδ T cell receptor. On the contrary, 30 dpi these metabolites could be also 
available in the environment as a consequence of the cytotoxic activity on infected cells probably 
due to the cytokines released by activated CD8+ cells. The peak of γδ IFN-γ+ T cells in the group 
treated with the commercial vaccine 30 dpi could be again explained by an increase of cytotoxic T 
cells that, through the killing of Mycoplasma-infected cells, could release ligands for the expansion 
of γδ cells. The high amount of γδ IFN-γ+ T cells 15 dpi in the group 3 (saponin vaccine) could be 
due to the cytokine milieu produced by CD4 memory cells expanded 7 dpi that could support γδ 
IFN-γ+ T cells increase. 
Conclusions  
The detection of T lymphocyte subsets responsible of the protection against CA, represents an 
important tool to evaluate the efficacy of available and experimental vaccines, and could be also 
useful to select the more immunogenic antigens for the inclusion in a subunit vaccine. On the 
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contrary the identification of a subset correlate to the infection could be useful as a biomarker of 
disease. 
Methods 
Experimental design 
Twenty-two ewes, belonging to Comisana breed, aged from 2 to 4 years, were microbiologically 
and serologically confirmed as negative for Mycoplasma spp and any other mastitis etiological 
agent. All animals were subjected to synchronisation of their estrum. Forty days after parturition – 
to allow new-borns sheep to receive natural colostrum from their mothers – the herd was divided 
into 4 groups of 5 animals. The two remaining sheep were chosen to be later experimentally 
inoculated with live Mycoplasma, as natural source of pathogens, but not considered in the data 
analysis. Three groups were treated with the proper dose of the same number of vaccines (as 
recommended by manufacturer instruction). The fourth was considered as control group. Vaccines 
tested in this experiment were supplied by different sources (Tab. 1): farm vaccine (inactivated with 
formalin and combined with Quil A as adjuvant) from internal Vaccine laboratory of Istituto 
Zooprofilattico Sperimentale della Sicilia (hereafter “farm” vaccine); commercial vaccine 
(inactivated with formalin and combined with Aluminium hydroxide as adjuvant) that was bought 
from a local veterinary pharmacy (hereafter “Commercial” vaccine); and a novel saponin-
inactivated vaccine, in which saponin acts as inactivant and adjuvant in the same time (hereafter 
“Saponin” vaccine).  
Three weeks after the first inoculation, all the animals were boosted with an identical dose of the 
same vaccine. Immunoglobulin levels were weekly monitored to determine the presence of an 
acquired immunity against M. agalactiae. In the meantime, in a separate paddock, the two selected 
sheep were intracisternally inoculated with a live strain of M. agalactiae. Microbiological and 
biomolecular analyses demonstrated that the CA induced in these sheep was exclusively due to M. 
agalactiae. At day 0 of the experiment, the infected ewes were put in contact with the other 
animals, thus allowing the herd to stay permanently in contact with sick animals, imitating natural 
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infection [12]. Immunological data were collected at days 0, 7, 15, 30 and 90 after challenge (Fig. 
1A). 
Challenge 
For inoculum preparation a field strain recently isolated from a Sicilian outbreak of CA, confirmed 
by biochemical and PCR analysis, was utilized. After isolation the strain was cultured in modified 
Hayflick broth (500 ml) [13] after 72 hours incubation at 37°C, the culture was harvested at 
10.000g for 30 min and re-suspended in the same volume of phosphate buffered saline (PBS) 
solution, pH 7.2. M. agalactiae antigen suspension was further stored in 1.5ml criovials and frozen 
at -80°C. Viable M. agalactiae antigen was quantified before inoculation by the method described 
elsewhere [13]. 
The challenge was designed in order to realize a system as more similar as possible to the natural 
infection. A 1.5 ml-inoculum containing 105 CFU of M. agalactiae was injected intracanalicularly 
into both halves of the mammary glands of 2 sheep. Milk samples collected from these ewes were 
tested in order to confirm the presence, the excretion of M. agalactiae and the absence of any other 
mastitis agents [13]. As previously reported by Tola and coll. [12, 14], all other remaining animals 
didn't receive any direct inoculum and they were simply left in contact with others and milked 
together. The Mycoplasma CFU was monitored both in infected and in-contact animals (data not 
shown). Twice a day, after milking the infected ewes, the operator would dip his hands in the 
infected milk and milk the vaccinated and control sheep [12]. The experiment was carried out in 
accordance with the Code of Practice for Housing and Care of Animal used in Scientific Procedures 
(EU Directive 2010/63/EU). The experiments were carried out with the authorization of the Italian 
Ministry of health (Decreto Ministeriale N° 101/2006 –A). The work was reliable using the animal 
facility of Istituto Zootecnico Sperimentale per la Sicilia (Palermo). 
Data and samples collection 
Blood, serum, milk, ocular and nasal swabs samples and clinical data about the presence or absence 
of mastitis, arthritis and keratoconjunctivitis were recorded weekly till the week 26 after challenge, 
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while immunological data were collected at days 0, 15, 30 and 90 after infection as previously 
shown in Fig. 1A. 
Serological and microbiological tests 
Screening for anti-M. agalactiae antibodies was performed utilizing a commercial ELISA kit 
(Institut Pourquier, France) following manufacturer instructions. The value of antibodies optical 
density were analysed with a statistical model of analysis of variance (ANOVA) for repeated 
measures. The confidence value was fixed at 0.05. The presence of M. agalactiae from infected and 
in-contact animals was confirmed by specific PCR and culturing milk and swabs samples as 
described elsewhere [15, 16]. Microbiological tests also included screening for conventional 
mastitis agents (data not shown). 
Antigen preparation and flow cytometric analysis 
A selected M. agalactiae strain was isolated from cultures in semi-solid medium (Mycoplasma 
Experience, UK; Mycoplasma broth and agar, Oxoid, USA) and radiated to be used as a source of 
antigenic in vitro stimulus for lymphocytes [3]. Peripheral Blood Mononuclear Cells (PBMC) were 
collected from whole blood and cultured as described elsewhere [3]. Cells were thus collected after 
48h of in vitro antigen exposure and flow-cytometric analyses were assessed. These assays were 
performed staining the cells with anti-surface-FITC-labelled mAbs and anti-IFN-γ PE-labelled 
mAbs at the concentration suggested by the suppliers in 100 µl PBS/0.1% Sodium Azide. Surface 
immunofluorescence was detected by anti-CD8 (FITC-labelled, clone CC63, mouse IgG2a, Serotec, 
U.K.), anti-CD4 (FITC–labelled, clone 44.38, mouse IgG2a, Serotec, U.K.), anti-WC1 (FITC-
labelled, clone 19.19, mouse IgG1, Serotec, U.K.); anti-CD45R0 (purified, clone GC42A1 mouse 
IgG1) and anti-CD45RA (purified, clone 73B1 mouse IgG1) stainings were assessed by indirect 
labelling using a rat anti mouse IgG1 (PerCP-labelled, cat.n. 340272, rat IgG). After three washes, 
cells were fixed and permeabilized by Leucoperm reagent set (Serotec, U.K.) and then incubated 
with anti-IFN-γ mAb PE-labelled (clone CC302, mouse IgG1, Serotec, U.K.) for 15 minutes at 4°C. 
After three washes, cells were collected using a FACS-CAN cytometer (Becton Dickinson, U.S.A.) 
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and analysed by CELL-QUEST PRO program (Becton Dickinson, U.S.A.). The data related to the 
cellular subsets of CD4+CD45R0+- CD4+CD45RA+- CD8+CD45R0+ and CD8+CD45RA+- and γδ+ 
T-lymphocytes were analysed and the values of the fluorescence were determined subtracting those 
of the corresponding negative controls that is the fluorescence of PBMC cultured with media alone 
and treated with the same reagents for staining. Each analysis was performed collecting 10000 
events of live lymphocytes previously physically gated. 
Statistics 
The Mann-Whitney test was used to analyse the significance between values of different groups; the 
confidence value was fixed at 0.05. 
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CA: Contagious Agalactia; MA: Mycoplasma agalactiae; dpi: days post infection, PBMC: 
Peripheral Blood Mononuclear Cells 
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Figures 
Figure 1 - Clinical trend of vaccinated and infected groups of sheep 
The figure 1A represents the scheme of the experimental design, indicating the time points before 
and after the infection (day 0). Fig 1B shows the incidence of clinical symptoms in the four groups, 
considered as presence of symptoms during the monitoring period of 90 days. During this period 
some animals recovered from the symptom, thus allowing the decrease of the incidence. All the 
main symptoms of CA were considered (mastitis, arthritis, conjunctivitis). 
Figure 2 - CD4 memory and naïve IFN-γ+ T cells during the observation period 
The figure 2A shows the relative percentages of CD4+CD45R0+IFN-γ+ and CD4+CD45RA+IFN-γ+ 
T-lymphocytes in CD4+IFN-γ+ cells. In panel B the absolute percentages of CD4+CD45R0+IFN-γ+ 
are shown. It can be noted that the comparison of the percentage of activated CD4+CD45R0+ T-
lymphocyte subset shows a significant difference between groups 3 and 2 and control group 
(p<0.05) at days 30 and 90 post-infection. 
Figure 3 - CD8 memory cells increase in sick animals 
The figure 3A shows the relative percentages of CD8+CD45R0+IFN-γ+ and CD8+CD45RA+IFN-γ+ 
T-lymphocytes gated on CD8+IFN-γ+ cells. The comparison of the absolute percentages of 
CD8+CD45R0+ IFN-γ+ T-lymphocyte subsets among groups, illustrated in panel B, shows the 
significant difference between non-protected groups (groups 4 and 1) and protected groups (2 and 3, 
p<0.05) at days 7 and 30 post-infection. 
Figure 4 - IFN-γ positive γδ T-cells trend in vaccinated and control groups 
The mean percentages of IFN-γ positive γδ T-cells in the time course of the experiment in the 
different groups of sheep is showed. 
Tables 
Table 1 - Overview of the vaccines formulations used in this experiment 
The group 1 was treated with PBS only in place of the vaccine injections. Groups 2, 3 and 4 were 
treated with a proper dose of vaccine, and boosted following the manufacturer instruction. 
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Agnone et al., Table 1 
Group # Vaccine  
 
Producer  Inactivation procedure Adjuvants 
1 None --- --- --- 
2 Farm vaccine  IZS Sicilia, Italy 0.4% formalin 200µl/ml Quil A 
 
3 Saponin vaccine  IZO  2 mg/ml saponin  
--- 
4 Commercial  Aglovax 0.2% formalin Aluminium hydroxide 
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Zoonoses include a broad range of diseases, that are becoming of great interest, due to the climate changing, that cause the
adaptation of vectors to new niches and environments. Host immune responses play a crucial role in determining the outcome
of infections, as documented by expansion of antigen-specific T cells during several zoonotic infections. Thus, understanding
of the contribution of antigen-specific T-cell subsets in the host immune response is a powerful tool to evaluate the diﬀerent
immunological mechanisms involved in zoonotic infections and for the development of eﬀective vaccines. In this paper we discuss
the role of T cells in some eukaryotic and prokaryotic infectious models.
1. Introduction
Zoonotic diseases are a significant burden on global econ-
omies and public health [1] and are due to the unaware
role of wild and domestic animals, which act as reservoir or
hosts of the etiological agents. More than 60% of emerging
infectious diseases are constituted by zoonoses and the
majority of these are increasing significantly over time [2].
In 2009 the World Organization for Animal Health (OIE)
has commissioned Civic Consulting to conduct a study on
the Cost of National Prevention Systems for Animal Diseases
and Zoonoses, estimating that in developing and transition
countries substantial diﬀerences in the public expenditure
for the National Prevention System for Animal Diseases
and Zoonoses exist, reaching from 10 million international
dollars to 167 million international dollars [3]. The impair
they cause should be attributed not only to human and
animal suﬀering but also to the hampering agricultural
production, the decreasing of food availability, and the
creation of barriers to international trade [1], as well as the
veterinary management, the maintenance of surveillance
plans, and the capillary control in the food industry chain of
production.
Many zoonotic agents are transmitted by vectors, others
by contaminated water or food, and others by direct trans-
mission. A broad range of pathogens can be responsible for
zoonoses, ranging from virus to prokaryotic to eukaryotic
(unicellular or multicellular), and the great diﬀerence in the
antigenic input for the immune system of the hosts implies
that many diﬀerent branches of immunity could be involved
in protection or pathogenesis.
T cells play a pivotal role in immune functions since they
are able to act not only diﬀerentiating in diﬀerent subsets
(including γδ T-lymphocytes and Cytotoxic T-Lymphocytes)
but also inducing the production of antibodies that inhibit
the pathogen spreading, both directly and with the help of
other branch of the immune system.
Homeostatic cytokines are those factors able to regulate
multiplication and diﬀerentiation of many cell types; T
cells are dependent on contact with IL-2, IL-7, and IL-15,
for their survival and intermittent homeostatic proliferation
[4]. T-helper cell diﬀerentiation is instructed by distinct
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environmental cytokines, that upregulate the expression of
lineage-specific transcription factors and inhibit the alternate
diﬀerentiation pathways [5]. The contact between the naı¨ve
T cell and the antigen induces the expression of IL-2 and
IL-2 receptor leading to the entry of the T cell into several
rounds of proliferation and to the diﬀerentiation in Th1,
Th2, Th17, and induced regulatory T (iTreg) cells. The
process consist of an intriguing cytokines puzzle, where IL-
4 plays a major positive feedback role in Th2 diﬀerentiation,
and IFN-γ, together with IL12, determines Th1 induction
[6]. IL6 and IL1 are necessary for Th17 production, while
the role of TGFβ needs still to be deeper investigated [7, 8].
Finally, activated naı¨ve CD4 T cells stimulated by TGF-β in
the absence of proinflammatory cytokines develop into iTreg
cells [9].
The complex network of cytokines function is resolved
in a balance from diﬀerent T-cell activation pathways
(Th1/Th2, Th1/Treg, Th2/Treg, Th1/NK, and/or γδ T
cells). Although T-cell-mediated immune response during
zoonotic infections is poorly studied, the facilities in the
setting-up experimental conditions make it good system
for a deeper investigation on the specific activation of T-
lymphocytes.
It is well known that protozoan, helminthic parasites, and
intracellular bacteria are able to survive within the host, in
spite of the activation of both innate and adaptive immune
response [10]. Zoonotic infections caused by eukaryotic
organisms are intriguing systems where the antigen-specific
T-cell expansion can be studied [11].
Helminthes have the ability to drive the diﬀerentiation of
naı¨ve CD4 T cells to the Th-2 subset of eﬀector cells which are
able to eliminate the pathogens by the actions of antibodies
induced by Th2 cytokines. During a protozoarian infec-
tion, protozoa are usually phagocytosed into macrophages,
previously activated by Th1 lymphocytes, and are able to
survive evading host immune response. As it happens in the
case of intracellular bacteria, infected cells loose the ability
to kill the pathogen, and Cytotoxic T-Lymphocyte- (CTL-)
mediated immune response is needed for the elimination
of microorganisms into macrophages [12] (Figure 1). The
naı¨ve T cells encounter the antigen in the peripheral lymph
node, develop toward eﬀector cells, and migrate to the site of
infection for the killing of infected cells. This process is finely
tuned by cytokines cross-talk and microbial ability to evade
host immune response.
B cells and humoral response play the main role in the
clearance of extracellular bacteria. Nevertheless, a certain
enrolment of T-cells has been demonstrated [13]. In this
paper, we draw attention on diﬀerent mechanisms of T-cell-
mediated immunity, in order to compare the mechanisms of
immune modulation induced by various zoonotic agents.
2. T Cells and Cytokines Induced by
Eukaryotic Zoonotic Agents
The nematode parasites Toxocara (T.) canis and T. cati
choose dogs and cats as definitive hosts, respectively. Some-
times, when embryonated eggs are accidentally ingested
by humans, larvae hatche in the small intestine, penetrate
the intestinal wall, and cause the larva migrans syndrome
[14]. Toxocariasis symptoms are classified according to the
organs aﬀected in visceral larva migrans (VLMs) and ocular
larva migrans (OLMs). In the latter toxocariasis pathological
eﬀects on the host are restricted to the eye and optical nerve
[15], while in the case of VLM, symptoms can persist for
more than one year and include abdominal pain, coughing,
headache, and normal or mildly elevated eosinophilia [16]. A
recent survey [17] emphasizes that the seroprevalence value
among humans is considerably high, thus demonstrating
the relevance of this pathology. T. canis is able to control
host immune response, through the modulation of cytokines
produced by immune cells. The immunomodulatory eﬀect
has been demonstrated in mice, where the stimulation of
normal macrophages with T. canis antigen in vitro induced
IL-1α, IL-6, IL-10, and TGF-β, but not IL-12 and TNF-α
[18]. Prototypical immune responses are characterized by
increased lymphoproliferation of CD4+ and CD8+ T cells,
increased production of IL-4 and IL-5, eosinophilia, and
augmented production of IgE, as previously described in
humans and mice [13–15]. As regards the immune response
in dogs, it has been demonstrated that T. canis is able to
induce antigen-specific IFN-γ production in pregnant dogs
and in their puppies [19]. Blood mononuclear cells (BMCs)
were isolated from pregnant dogs and their puppies and
were cultured in the presence of ESAg (Excretory/Secretory
Antigen of T. canis). Cytokine levels were tested in cultures’
supernatants by ELISA, and it was noted that IL-10 concen-
tration increases during pregnancy in infected animals while
IFN-γ production decreases. On the contrary IL-10 concen-
tration decreases with the age of infected puppies while IFN-
γ amount increases. It appears clear that immune cells of
infected dogs undergo T. canis-induced modifications. These
modified pattern of cytokines detected in T. canis could
be due to a synergistic eﬀects of physiological changes of
immunity during pregnancy and in the first month of life,
and/or direct eﬀects mediated by parasite interaction with
host immunity. The finding that IL-10 and IFN-γ levels were
significantly modified in infected pregnant dogs and their
puppies provides new perspectives for immunotherapeutic
interventions based on switch of Th2 to Th1 cytokine pattern
in females before pregnancy.
Another system to understand the role of T cells in
eukaryotic zoonotic infections is echinococcosis. Alveo-
lar echinococcosis is caused by the metacestode stage of
Echinococcus multilocularis. The definitive hosts are the
foxes, which release Echinococcus eggs in the foecal matter,
spreading them in the environment. Little rodents acquire
the infection by ingesting eggs and carry the infection in
their liver. Humans are aberrant intermediate hosts [20].
In humans, metacestode stage of the worm aﬀects the liver,
where an abdominal mass develops; other symptoms may
arise like abdominal pain, jaundice, and liver failure [21].
The severity of the disease is dependent on the genetic
background of the host and on the balance between the
Th1-related immune response, associated with protection,
and the induction of the immune tolerance by the parasite
itself [22]. In experimentally infected C57BL/6J mice the
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Figure 1: Schematic network of cells and molecules in response to zoonotic agents. An “oversimplified” scenario constituted by various
cells and molecules involved both in binding of epitopes derived from pathogens and in the eﬀector mechanisms hereby represented. APCs
bind zoonotic derived epitopes and present them to various types of lymphocytes, in the context of MHC molecules and/or Toll-Like
Receptors (TLRs). These subsets, producing diﬀerent cytokines, could activate eﬀector “protective” mechanisms involving macrophage
killing, cytotoxic activity by CTL and/or CD4, and release of various cytokines, thus leading to the damaging of zoonotic pathogens.
The killing by CTL, that could be not only CD8 but also NK cells, could be also due to an ADCC phenomenon with the contribution
of antizoonotic epitopes,-specific antibodies.
promotion of the disease seems to be associated with the
expansion of diﬀerent T-cell subsets: spleen cells harvested at
diﬀerent time points after infection were stimulated in vitro
with a crude parasite extract. A strong CD4+ proliferative T-
cell response was observed at the early stage of infection, and
IFN-γ, IL-2, and IL-5 were produced within the first weeks
after infection whereas the detection of IL-10 was slightly
delayed [23]. Cystic echinococcosis is caused by E. granu-
losus. The main domestic cycle is maintained between dogs
and sheep, with man as accidental intermediate host. The
disease is acquired by ingesting eggs, originating from the
faeces of definitive hosts (dogs, wolves, and other carnivores)
[24], and it typically aﬀect, the liver. It is often asymptomatic,
but in case of rupture of the cyst, secondary infection
and anaphylactic reaction can occur. The most frequent
complications are pain, obstructive jaundice, cholangitis and
sometimes shock [25]. It has been demonstrated that a
restimulation of PBMC from aﬀected patients with the crude
antigen induces an upregulation of IL-5 and IL-10 [26] as
well as a downregulation of IL-1 and TNF-α mRNAs [27].
The opportunistic parasite Toxoplasma gondii belongs
to the phylum apicomplexa. Feline acts as definitive hosts
in its life cycle, while mammalians, including humans,
are intermediate hosts. Human toxoplasmosis is usually
asymptomatic or paucisymptomatic, but the parasite is able
to cross the intestinal barrier and disseminate through the
body, reaching muscle, central nervous tissues, eyes, and
placenta [28]. Congenital toxoplasmosis may hesitate in
retinochoroiditis and/or mental abnormalities [29].
The infection by T. gondii induces a strong cellular
response essential for the host resistance [30]. In particular,
it has been noted since 1990 that upon an in vitro stimulation
with T. gondii antigen, a strong CD8+ T-cells response,
sustained also by CD4+cells expansion, is mounted [31].
The role of CD4+ in the activation of CD8+ has been
demonstrated in mice [32], where the generation of optimal
numbers of antigen specific CD8+ eﬀector T cells was found
to require CD4+ T-cells help. The parasite is also able to
induce a strong natural killer (NK) cells activation and
macrophages production of IL-12, both ending in a massive
IFN-γ production. The IFN-γ production is sustained by
γδ-T lymphocytes [33] that help CD4+ and CD8+T cells to
restrict parasite growth until the emerging of the complete
adaptive response. It has been recently demonstrated that
the CD8+ T-cells response is sustained both by “homeostatic
cytokines” IL-15 and IL-7 and that the absence of IL-15 or
IL-7 alone does not aﬀect CD8+ T cell activation during acute
toxoplasmosis [34], thus suggesting that these cytokines
could act in synergy. Immune response of congenitally
infected newborns to T. gondii undergoes to a process that
leads to anergy [35, 36], probably due to a developing
immune system of the infant. In this case, both αβ- and γδ-T
cells become unresponsive when stimulated with T. gondii-
specific antigen. Nevertheless, Vδ2+ γδ T cells are able to
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lose tolerance before αβ-T-cells, and to confer protection
against the chronic phase of infection in congenitally infected
children [37]. Indeed, γδ T cells are considered to undergo
peripheral tolerance, thus persisting in blood longer than αβ
T lymphocytes which are deleted in the thymus during T.
gondii infection [37].
A useful model to better understand immune response
to eukaryotic zoonotic agents is constituted by Leishmaniasis
and its related immunity. Leishmaniasis is a vector-borne dis-
ease caused by obligate intramacrophage protozoan parasite
of the genus Leishmania and its incidence is increasing in
nonendemic areas due to changing patterns of international
travel and to population migration [38]. Visceral leishma-
niasis (VL) or kala-azar is one of several diseases caused by
more than 20 species of the protozoan parasite Leishmania.
The infection tends to aﬀect mainly children, but immuno-
suppression and HIV increase the possibility to contract the
illness. The common symptoms are fever, malaise, shivering
or chills, weight loss, anorexia, and discomfort in the left
hypochondrium [39]. In experimental L. major infections
genetically resistant mice develop a T-cell response domi-
nated by a CD4+ (Th1) phenotype characterized by IFN-γ
secretion while in susceptible mice the dominant response
is a CD4+ (Th2) phenotype characterized by interleukin
IL-4, IL-5, and IL-13 secretion [40]. These observations of L.
major in mice led to the emergence of the Th1/Th2 paradigm
as opposing cytokine responses in the control of infections
[41, 42]. The balance of Th1 to Th2 responses determines the
outcome to infection. In the natural disease both Th1 and
Th2 cellular subtypes are activated. Resistance to infection
depends on production of cytokines such as IFN-γ, TNF,
IL-2, and IL-12. These cytokines stimulate cell-mediated
immunity which eliminates the infection activating leish-
manicidal activity of macrophages [41, 42]. The infection
in dogs shows diﬀerent clinical presentations, from subclini-
cal/asymptomatic to a fully developed disease, depending on
the host’s immune responses. The Th1/Th2 dichotomy is not
clear in the diﬀerent forms of canine leishmaniases, because
it depends on physiological status of the infected subject.
The production of IL-4, IL-5, IL-6, and IL-10, which in turn
promote B-cell proliferation and antibody production, is the
cause of susceptibility of dogs, which become not able to
control the infection [43–45]. Our experience is focused to
evaluate cytokine expression level with a quantitative real-
time PCR assay to measure expression levels of cytokines
relative to either Th1 or Th2 patterns in the blood of nat-
urally infected asymptomatic dogs. High expression levels of
IL-2 and IFN-γ were detected at the first observation, which
decreased over time. Opposite cytokine-based eﬀects were
detected in infected dogs. In those that had a clinically evi-
dent outcome, IL-2 and IFN-γ were initially not expressed,
but their levels suddenly increased with the appearance of
clinical signs [43]. Furthermore from our study it was con-
firmed that IL-12 represents a marker of active disease, while
IL-18 cannot be involved in the progression from asymp-
tomatic to active disease. These data suggest that response
to Leishmania in the dog does not fit into a specific cytokine
profile.
3. Antigen-Specific T Cells and
Derived Cytokines Detection in
Prokaryotic Infections
Among prokaryotic microorganisms able to cause zoonotic
disease, Leptospira, Brucella, and Mycobacteria oﬀer suitable
models to analyze the role of immune response against these
pathogen since the related immunity could involve diﬀerent
antigen-specific T cell subsets. Leptospira interrogans is one
of the main causative agents of leptospirosis. The pathogen is
able to persist in the kidneys of infected (wild and domestic)
animals and is spread in the environment through their
urine. It is transmitted to humans through skin abrasions
and causes haemorrhage, diarrhoea, renal impairment, and
aseptic meningitis [46]. Phagocytosis is the main process
that allows the clearance of the pathogen, and it has been
recently demonstrated that the bacteria undergo a complex
transcriptional regulation in order to evade host immune
response [47]. In particular they downregulate the major
OMPs (Outer Membrane Proteins) through the action of a
hypothetical transcriptional factor. It is well accepted that
humoral immunity has an important role for the elimination
of extracellular bacteria, but sometimes antibodies alone
could not be suﬃcient, especially in the case of L. borg-
petersenii serovar Hardjo [48]. In this and other cases, IFN-
γ plays an important role for the activation of macrophages
and the production of IgG2 class of immunoglobulins [49,
50]. The involvement of a cellular immune response has been
recently demonstrated: a strong Th1 response was recorded
by the observation of the IFN-γ production following the
in vitro stimulation of vaccinated bovine PBMC with the
specific antigen [51]. The results from vaccinated animals
indicated that approximately two-thirds of IFN-γ+ cells were
within the CD4+ T-cell population while the remaining one-
third were γδ T cells [51]. Furthermore, Guo et al. have
recently reported the existence of specific cytotoxic CD8+
T cells in patients with leptospirosis and have detected a
potential epitope of the leptospiral protein LigA, able to
elicit specific cytotoxic T-lymphocyte (CTL) responses [13].
Naiman and Guo suggest that Th1 response to Leptospira
requires the cooperation between two or more T cell subsets
like γδ, CD8+, CD4+, and so forth. In Leptospira-infected
hamsters a new soluble factor was shown to be important
for the protection: IP-10 [52]. This evidence points to T
cell-derived chemokines in zoonosis. These proteins are able
to induce cell migration from lymphoid organs to aﬀected
tissues and they are also considered markers of T cell matu-
ration [53]. Indeed, future approaches for a deeper analysis
of T cell response in zoonoses could be comprehensive of
the characterization of the released chemokines and their
receptors.
A very hot field in veterinary immunology is represented
by T cell responses against intracellular bacteria. Tuberculosis
and Brucellosis remain major worldwide health emergencies
among zoonotic bacterial infections, and a better under-
standing of the host immunological reactions to these
pathogens is fundamental for improving both therapies and
vaccines strategy, as well as to prevent dissemination of the
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infectious agents in the herds. Tuberculosis causes in host
mild fever and a wide range of symptoms depending on
the localization of the Mycobacterium (pneumonia, kidney
failure, meningitis especially in children, etc.) [54].
Animal tuberculosis is mainly observed in cattle (less
frequently also in horses, swine, dogs, cats, sheep, and
goats), caused by Mycobacterium (M.) bovis, and in birds,
due to M. avium. Human tuberculosis is mainly caused
by M. tuberculosis, but around 10% of total infections are
due to M. bovis, typically as professional disease, while M.
avium can cause disease in immunodeficient patients [55].
Dogs and parrots are highly susceptible to M. tuberculosis
by the contact with infected humans. T-lymphocytes play
a central role in the control of M. tuberculosis replication,
as this infection evokes a strong cell-mediated immune
response. Protective immunity against M. tuberculosis is
due to adaptive cellular immune responses, and protective
immunity correlates to the induction of T cell cytokines
following antigen specific stimulation. CD4+ and CD8+ T
cells are key components of anti-mycobacterial immunity
[56, 57]. Both IFN-γ production and cytotoxic activity
against infected target cells contribute to bacteria killing with
lysis of infected cells [58, 59].
T cells response after in vitro stimulation of human
PBMCs with M. tuberculosis-specific antigens (e.g., Purified
Protein Derivative, or PPD) can be assessed by measuring
intra- and extracellular IFN-γ [60]. The severity of M.
tuberculosis infection may be detected by measuring CD4+
and CD8+ T cells, as their numbers markedly decrease
in patients with severe tuberculosis, which can be a sign
of suppressed cellular immunity in these patients [60].
Particularly, patients with active TB have a lower number
of both CD4+ T cells and their naı¨ve, eﬀector, and late
diﬀerentiated memory subsets [61], with a drop in all
the three phenotypic populations. Similarly, CD8+ T cells
counts were also significantly diﬀerent between infected
and negative patients. At least partially, these disturbances
seem to be restored to baseline after successful therapies
[61].
In our experience with cattle [62] it has been showed
that cocktails of epitopes from ESAT-6 (the 6 kDa early
secretory antigenic target of Mycobacterium tuberculosis) are
recognized with high frequency by CD8+ T lymphocytes of
naturally infected cattle, thus confirming a role of ESAT-
6 specific CD8+ T cells in the response to M. bovis.
Nevertheless, the number of IFN-γ-positive CD8-negative
cells was larger than that of IFN-γ+ CD8+ T cells, indicating
that IFN-γ+ CD8+ T cells are not the dominant subset
responding to stimulation with ESAT-6-derived peptides.
Nevertheless, ESAT-6-specific T-cell expansion could be
useful to detect the early phase of the disease thus limiting
the dissemination of M. bovis.
Other cytokines such as TNF-α, IL-2 [63], MCP-2 [64],
and IP10 [65] were shown to be involved in the anti-
mycobacterial immune responses in humans; Th1- and
other cytokines interacting with macrophages are commonly
considered as mediators of anti-mycobacterial biological
agents. When reagents for the detection of these cytokines
in vertebrates will be available, it could be intriguing to
understand the role of these cytokines in mycobacterial
immune response also in veterinary infections.
Brucellosis is a multisystemic disease with a broad range
of symptoms, usually beginning with acute febrile illness,
headache, malaise, and myalgia. Gastrointestinal signs as
vomiting, anorexia, and nauseamay also occur [66]. Humans
are susceptible to Brucella (B.) suis, B. Abortus, and B.
canis, and, more frequently, to B. melitensis. The disease
can be transmitted by both direct and indirect contact with
infected animals or secretions, or by eating contaminated
food (especially unpasteurized milk and fresh cheeses).
Interhuman transmission is extremely rare [67].
Brucella invades and proliferates within monocytes. In
addition to the central role of monocytes/macrophages,
other cells of the innate immune response are recruited
and influence the interaction between bacteria and host.
For instance, human Vγ9Vδ2 T cells play an important role
in the early response to infection [67], and their number
dramatically increases in the peripheral blood of patients
with acute brucellosis [68], reaching 30% of the total T
lymphocytes. Vγ9Vδ2 T cells are specifically stimulated by
Brucella to secrete TNF-α, important for the autocrine acti-
vation of macrophage functions, IFN-γ, and other cytokines
[69]. In vitro, Vγ9Vδ2 T cells exhibit a strong cytotoxicity
against Brucella-infected cells. Vγ9Vδ2 T cells decrease the
development of intracellular Brucella releasing lytic granules
and/or acting through Fas-mediated signals to lyse infected
macrophages. It was also shown that the recruitment of
NKG2D by its ligands is suﬃcient to induce cytokine pro-
duction and the release of lytic granules thus increasing the
TCR-triggered responses of Vγ9Vδ2 T cells. The interaction
between NKG2D and its main ligand expressed on Brucella-
infected macrophages, UL16-binding protein 1 (ULBP1), is
involved in the inhibition of bacterium development [69]. As
demonstrated in the case of Vγ9Vδ2 T cells, it was shown that
also NKT cells are able to exert an anti-Brucella in vitro activ-
ity, either secreting cytokines or killing infected macrophages
[70]. NKT and Vγ9Vδ2 are considered as quite unrestricted
T cells as they do not recognize MHC and peptides, but
they expand following stimulation with nonpolymorphic
MHC-like molecules CD1 and/or with nonpeptidic and
glycolipid ligands. A cross-talk between Vγ9Vδ2 and NKT,
due to cytokines released in the milieu, could be responsible
for the activation of NKT in synergy with a possible
upregulating role of CD1 molecules expression exerted by
Brucella antigens. The previously described subsets activated
during Brucella infection could exert a protective role during
Brucella infection through their potent cytotoxic activity.
4. Concluding Remarks
Each microorganism hereby evaluated elicits a particular
type of immune response. A “classical” Th1-mediated
protective immune response was detected during zoonotic
infections like leishmaniasis or tuberculosis. Toxoplasma-,
Brucella- and Leptospira-induced immune response involves
a wide range of T cells including γδ and NKT cells. The in
vitro and ex vivo detection of T cells upon stimulation with
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the specific antigen allows going insight in the host/pathogen
interaction. The equilibrium established after such dialogue
is critical for the further ongoing of the infection. A
complex network of T cells, cytokines, and chemokines could
be studied to better understand the interactions between
zoonotic agents and receptors of innate and adaptive immu-
nity. This tool could be useful to develop vaccines and
immunotherapies in the next future.
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primers designed for the specific PCR amplification of A. ovis and A. marginale allow to easily detect 
and discriminate between the two pathogens, thus avoiding the time-consuming sequencing or multi-
gene amplification procedures. This PCR provides a tool for the detection of A. ovis and A. marginale in 
ticks and in wildlife and domestic hosts. 
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Abstract 
Anaplasma ovis and Anaplasma marginale are tick-transmitted bacteria that cause 
anaplasmosis in domestic and wild animals. Recent results show that some domestic and wild 
animals and ticks are susceptible to both A. ovis and A. marginale, thus supporting the need to 
differentiate between these species in hosts and ticks diagnosed with Anaplasma infection. 
However, although anaplasmosis is one of the most common diseases of grazing animals 
worldwide, rapid and effective tests are not available for the detection and discrimination 
between these two Anaplasma species. The objective of this research was to develop an easy 
and reliable method to identify and discriminate between the closely related pathogens, A. 
ovis and A. marginale. A. ovis and A. marginale major surface protein 4 (msp4) gene 
sequences were retrieved from different geographic strains and aligned to design two set of 
primers in a region with significant differences between the two species, but completely 
conserved among strains. PCR reactions using these primers were 100% species-specific and 
detected all strains from each pathogen previously identified with other methods. The two set 
of primers designed for the specific PCR amplification of A. ovis and A. marginale allow to 
easily detect and discriminate between the two pathogens, thus avoiding the time-consuming 
sequencing or multi-gene amplification procedures. This PCR provides a tool for the 
detection of A. ovis and A. marginale in ticks and in wildlife and domestic hosts. 
 
Keywords: Anaplasma, Diagnostics, major surface protein 4, Polymerase Chain Reaction 
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1. Introduction 
The genus Anaplasma (Rickettsiales: Anaplasmataceae) includes tick-borne pathogens that 
impact human and animal health (Dumler et al., 2001; Kokan et al., 2004). The genus 
Anaplasma includes the species A. marginale, the type species that infects ruminants and A. 
ovis, which infects sheep, goat and deer. Also included in this genus are other species such as 
A. centrale, A. bovis, A. platys and A. phagocytophilum. A. marginale and A. ovis infection 
could result in anaplasmosis, a mild to severe intraerythrocytic disease that produces 
considerable economic losses in some regions (Kokan et al., 2004). 
It has been generally accepted that A. marginale infects cattle while only sheep and goats are 
susceptible to A. ovis (Kokan et al., 2010). However, it has been shown that deer species are 
susceptible to both A. marginale and A. ovis (de la Fuente et al., 2005a, 2006, 2007, 2008; 
Kuttler, 1984), and recent reports provide evidence for possible A. ovis infection in cattle 
(Hornok et al., 2010, 2011). Additionally, some tick species are also vectors of both of these 
pathogens (de la Fuente et al., 2005a, Torina et al., 2008). These results support the need to 
differentiate between A. marginale and A. ovis in domestic animals, wild animals and ticks 
diagnosed with Anaplasma infection. 
Major surface proteins (MSPs) play a crucial role in the interaction of Anaplasma spp. with 
host cells and they are subjected to selective pressures exerted by host immune systems 
(Brayton et al., 2006; de la Fuente et al., 2005c; Dunning Hotopp et al., 2006; Kocan et al., 
2004). 
MSP4 is an immunodominant outer membrane protein with orthologs in all Anaplasma spp. 
examined so far (de la Fuente et al., 2005c). The msp4 gene has been used for phylogenetic 
studies providing information about the biogeography and evolution of Anaplasma spp (de la 
Fuente 2005b, 2005c, 2007). 
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MSPs PCR has been used for the diagnosis of Anaplama infection (de la Fuente 2005a, 
2005b, 2005c; Hornok 2010, 2011, Torina et al., 2008). Unfortunately, although very 
sensitive and easy to perform, this method is not able to discriminate between A. ovis and A. 
marginale. In a recent OIE publication (OIE Manual, 2008), they report that laboratories 
running this PCR assay should recognise problems associated with the inability to 
discriminate between some Anaplasma spp., thus requiring an additional step such as 
restriction enzyme analysis, Southern blot hybridisation or sequencing that can confirm the 
species msp amplified by PCR. However, these methods are expensive and time-consuming, 
thus requiring the development of reliable methods to identify and discriminate between the 
closely related Anaplasma spp. 
 
2. Materials and methods 
2.1. Blood samples and DNA extraction 
Eight cattle, sheep and goat field samples were selected to validate our procedure. Samples 
were collected in different farms to increase the probability of finding different Anaplasma 
spp. strains. Genomic DNA was purified from blood samples using a DNA extraction kit
 
(Invitrogen PureLink Genomic Mini kit). DNA extracted from uninfected animal blood 
samples were used as negative controls. All the DNA samples were examined both using a 
spectrophotometer method (Nanodrop™ Thermo Fisher Scientific, Wilmington, USA) and by 
16S rDNA PCR (Stuen et al., 2003), to test their quantity and quality. The Anaplasma spp. 
msp4 gene was amplified by PCR as reported previously (de la Fuente et al., 2003), using 
primers that amplify both A. marginale and A. ovis msp4 (Table1). The amplicons were 
sequenced in order to identify the species.  
2.2 Design of PCR primers  
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A. marginale msp4 gene sequences were selected from strains identified in the following 
countries: USA (GenBank accession numbers AF428081, AF428088, AY010252, AY010254, 
(AY010253), France (AY010249), Mexico (AF428085, AF428089, AF428084, AF428083), 
Argentina (AF428086, AF428087), Brazil (AF428082), Nigeria (EU106082), and Hungary 
(EF190508). A. ovis msp4 gene sequences were selected from strains identified in the 
following countries: Italy (EU436161, EU436160), USA (DQ674246, DQ674249, 
DQ674248, DQ674247), Hungary (EF190509, EF190510, EF190511, EF190512, EF190513), 
Iran (EU925811) and Spain (EF067341). 
The msp4 sequences were aligned using ClustalW2 (Larkin et al., 2007) and analyzed to 
identify an appropriate region to design the two set of primers. The designed primers were 
analyzed and adjusted so that 3' end hairpin ΔG values were lower than -2 kcal/mol and the 
ΔG values of internal hairpin were lower than -3 kcal/mol. Forward and reverse primers had 
similar melting temperatures. 
2.3 PCR conditions optimization 
In order to set up the two PCR reactions, different melting temperatures, ranging from 58 to 
64 °C, were tested, as well as different MgCl2 concentrations (from 1.2 to 2 mM) to assure the 
best ratio between specificity and sensitivity. Many different commercial Taq polymerases 
were also tested, but the differences among them were not significant (data not shown). The 
reactions were always conducted in a final volume of 25 μl. The obtained PCR products were 
visualized by UV lamp in a 1.5% agarose gel containing 0.1µg/ mL ethidium bromide.  
2.4 Design of PCR primers  
The msp4 gene sequences derived from 15 and 13 strains of A. marginale and A. ovis, 
respectively were aligned to design two set of primers in a region with significant difference 
between the two species, but completely conserved among strains. In particular we took 
advantage of a region of A. marginale msp4 at nucleotide position 120, harbouring a deletion 
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of three nucleotide not traceable in A. ovis msp4. The primer forward were designed between 
nucleotide positions 113 and 131 of A. marginale and between nucleotides 114 and 134 of A. 
ovis. The primers reverse were designed between nucleotide positions 435 and 456 of A. 
marginale and between nucleotides 438 and 460 of A. ovis. 
The primer set specific for A. marginale was composed by the forward primer 
AmargMSP4Fw (5’-CTGAAGGGGGAGTAATGGG-3’) and the reverse primer 
AmargMSP4Rev (5’-GGTAATAGCTGCCAGAGATTCC-3’). The primer set specific for A. 
ovis included the forward primer AovisMSP4Fw (5’-TGAAGGGAGCGGGGTCATGGG-3’) 
and the reverse primer AovisMSP4Rev (5’- GAGTAATTGCAGCCAGGGACTCT- 3’). 
2.5 PCR amplification 
The optimized PCR conditions were established as follows: reaction buffer 1x, 0.4 μM of 
each primer, 1.5mM of MgCl2, 0.2 mM of dNTP, 1.25 U of Taq Polymerase (Invitrogen Taq 
DNA Polymerase). The thermal profiles of PCRs were: 10 sec at 95°C for denaturation, 
followed by 30 cycles with denaturation at 94°C for 30 sec, annealing at 62°C for 15 sec for 
A. ovis and 60°C for 15 sec for A. marginale, and extension at 72°C for 30 sec. The final 
extension step was 5 min at 72°C.  
2.6 Cloning and sequencing 
Once optimized, PCRs were used to amplify A. ovis and A. marginale msp4 region from all 
the selected samples. PCR products were randomly selected, purified by a PCR and gel 
purification kit (Promega Wizard SV Gel and PCR Clean-up System), cloned into a cloning 
vector (Invitrogen pCR2.1 TOPO TA cloning kit) and sent for sequencing (Macrogen, Inc., 
Seoul, South Korea) both strands to confirm the identity of the amplicons for both A. ovis and 
A. marginale msp4.  
2.7 Specificity and sensitivity 
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To
 
characterize the specificity of the reactions, the two set of primers were used to analyze 
samples positive by PCR (Table 1) for A. phagocytophilum, A. platys, Ehrlichia canis, 
Rickettsia conorii, Coxiella burnetii, Babesia ovis, Babesia bovis, Babesia bigemina, Babesia 
canis, Babesia gibsoni, Babesia caballi, Babesia microti, Theileria equi, and Theileria 
annulata. Samples positive for Anaplasma spp. PCR but negative for A. phagocytophilum, A. 
ovis and A. marginale were also tested. Controls included reactions without DNA template 
and with DNA from Anaplasma-negative blood samples. Serial dilutions of a quantified 
plasmid DNA containing the A. ovis and A. marginale msp4 inserts were done and the PCR 
sensitivity was calculated in terms of pg of DNA per µl. 
 
3. Results 
Selected field samples, 8 positive for A. marginale and 8 positive for A. ovis, were amplified 
using the specific set of primers AmargMSP4Fw and AmargMSP4Rev, as well as 
AovisMSP4Fw and AovisMSP4Rev with the optimized PCR conditions. All cattle samples 
gave an amplicon of the expected size (344 bp) when amplified with primers specific for A. 
marginale and resulted negative when amplified with primers specific for A. ovis (Fig. 1). All 
sheep and goat samples gave an amplicon of the expected size (347 bp) only when amplified 
using the set of primers specific for A. ovis (Fig. 2). Some PCR products were randomly 
selected, sequenced and confirmed the specificity of the reactions. In particular two PCR 
products, one from A. ovis and one from A. marginale, were cloned and their sequences 
showed a percentage of identity with the closest strain equal to 100% (GenBank #HM063433) 
and 98.8% (GenBank #AF428081), respectively. The sequences obtained were submitted to 
GenBank (Accession numbers JF714148 and JF714147).  
All the samples positive for other related pathogens resulted negative using the newly 
designed primers. These results demonstrated that the new PCRs were specific and able to 
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differentiate between A. marginale and A. ovis with a sensitivity equivalent to 0,5 pg/μl for A. 
marginale and 0,005  pg/μl for A. ovis. (Figs. 3a and 3b). 
 
4. Discussion 
Anaplasmosis is one of the most spread tick-borne diseases not only in Mediterranean 
countries, but also in all tropical and sub-tropical regions of the world. The diagnostic PCRs 
used for A. ovis and A. marginale did not allow differentiation between these pathogens 
without the support of other techniques such as sequencing and multi-gene amplification. To 
resolve this deficiency in screening for these two pathogens, we developed a new sensitive 
PCR based on two different set of primers specific for the detection and differentiation 
between A. ovis and A. marginale. 
A. ovis and A.marginale have been detected not only in their natural hosts, but also in ticks 
that become persistently infected (Kokan et al., 2010). Wild ruminants act as reservoirs for A. 
ovis and A.marginale.( de la Fuente et al., 2005a, 2006, 2008; Krier et al., 1963; Kuttler, 
1984; Zaugg, 1987, 1988; Zaugg et al., 1996).
 
Recently, a possible A. ovis infection in cattle 
has been reported (Hornok et al., 2010, 2011), supporting previous experiments conducted by 
Kuttler (Kuttler, 1981). Little is known about the role of wild ruminants in the epidemiology 
of A. ovis and A.marginale (de la Fuente et al., 2005a). However, these results suggest that 
some hosts can act as reservoirs of both A. ovis and A. marginale. 
Recent works have focused on the presence of pathogens in ticks for epidemiological studies 
and to develop surveillance strategies. Ticks are the natural vectors of both A. ovis and A. 
marginale and some tick species can transmit both of these pathogens (de la Fuente et al., 
2005a; Torina et al., 2008). Additionally, recent reports have shown evidence of simultaneous 
infection with two or more Anaplasma spp. in ticks, deer and cattle in different areas of the 
world (Aubry et al., 2011; de la Fuente et al., 2005a). 
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These results support the need to differentiate between A. marginale and A. ovis in domestic 
animals, wild animals and ticks diagnosed with Anaplasma infection. 
In summary, the sensitive and species-specific PCRs developed here for the detection and 
differentiation between A. ovis and A. marginale have the potentiality to become an easy and 
fast tool for the diagnosis of A. ovis and/or A. marginale infection in ticks and vertebrate 
hosts.  
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Table 1. PCRs used for pathogen detection 
 
Assay Primers Target 
Amplicon 
size (bp) 
A. ovis/A. marginale
7 
MSP43 / MSP45 msp4 851 
Anaplasma spp.
 30 16SANAF / 
16SANAR 
16S rRNA 467 
A. phagocytophilum
9 MSP4AP5 / 
MSP4AP3 
msp4 849 
A. platys
20 
EPLAT-5 / ERB2 16SrRNA 780 
Ehrlichia canis
17 
ECC / ECB 16SrRNA 480 
Rickettsia conorii
33 
Tz 15-19/Tz 16-20 17KDa 246 
Coxiella burnetii
31 
Q3 / Q5 htpB 501 
Babesia ovis
1 
Bbo-F /Bbo-R ssu rRNA 549 
Babesia bovis
16 
BOF/BOR RAP 1 356 
Babesia bigemina
16 
BiIA / BiIB RAP 1 278 
Babesia canis
5 
PIROA / PIROB ssrRNA 400 
Babesia gibsoni
27 
PIRO A1 /Piro B 18SrRNA 450 
Babesia caballi
3 
Bc48R3 / Bc48F1 
48KDa 
rhoptry 
protein 
530 
Babesia microti
29 
BAB 1 / BAB 4 ssrRNA 238 
Theileria equi
3 
EMA5 / EMA6 
merozoite 
antigen 1 
268 
Theileria annulata
6 
N516 / N517 30KDa 721 
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Figures legends 
 
Figure 1. AmargMSP4Fw/AmargMSP4Rev primers amplify a specific band of 344 bp only 
in samples positive to A. marginale (lanes from 9 to 16) but not in samples positive to A. ovis 
(lanes from 1 to 8). Lane 17: negative control, lane 18: 100-bp ladder, lane 19: positive 
control. 
 
Figure 2. AovisMSP4Fw/AovisMSP4Rev primers amplify a specific band of 347 only in 
samples positive to A. ovis (lanes from 1 to 8) but not in samples positive to A. marginale 
(lanes from 9 to 16). Lane 17: negative control, lane 18: 100-bp ladder, lane 19: positive 
control. 
 
Figure 3. Sensitivity of the PCR method. Ethidium bromide stained agarose gel 
electrophoresis of amplification products from 10-fold diluted samples (from 50ng/μl to 5x10-
8 
ng/μl – lanes 1 to 10). Lane N: negative control, Lane M: 100-bp ladder. (a): A. marginale 
sensitivity: the value resulted  to be 0,5 pg/μl. (b) : A. ovis sensitivity: the value resulted  to be 
0,005 pg/μl. 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
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For the control of tick-borne diseases a deeper knowledge about the incidence and 
prevalence of the tick species involved in their transmission, as well as their role as 
pathogens vectors, would be helpful. Pathogens belonging to Anaplasma, Ehrlichia, 
Rickettisa and Coxiella cause important pathologies in animal and human. In our study 
we have analysed the ticks to detect the presence of these pathogens, in order to 
evaluate the tick species mainly involved in the transmission of disease. During the 
period 2004-2010, 5349 PCRs were performed in tick samples collected from infested 
animals or questing ticks collected in Sicily. Ticks were tested by specific PCRs for 
Anaplasma spp, A.marginale, A.phagocytophilum, Ehrlichia spp, Rickettsia spp and 
C.burnetii. Prevalence was calculated for each pathogen in different tick species. The 
pathogen Anaplasma spp was found in all the tick species tested; the highest prevalence 
was calculated in Hy. marginatum (17,7%) followed by Rh. bursa, Rh. turanicus, D. 
marginatus and I. ricinus (prevalence ranging from 10,2% to 8,2%), while Hy. 
lusitanicum and Rh. sanguineus had prevalence value less than 2,0%. A. marginale was 
isolated only from Rh. bursa (3,8%) and Rh. sanguineus (2,8%). Interestingly, A. 
phagocytophilum, was detected in Hy. marginatum (15,0%) Rh. turanicus (9,4%), 
Rh.bursa (6,1 %). I. ricinus had a prevalence of 5,7%. Ehrlichia spp showed a highest 
prevalence in D .marginatus (9,4%). As concerns Rickettsia spp prevalence, D. 
marginatus (34,4%), Rh. sanguineus (29,9%) and Hy. marginatum (20,8%) were the 
tick species with highest values. The Rickettsia prevalence for all the other species 
ranged from 10,3% to 1,6%. Finally, C. burneti was mostly present in Hy. marginatum 
(8,9%) and Hae. punctata (6,3%). Taken together, our data support the idea that there’s 
a significant difference in the ability of the tick vector to transmit different pathogens. 
Keywords: Ixodidae, Anaplasma, Ehrlichia, Rickettisa , Coxiella, Italy 
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Introduction 
Ticks (Acari: Ixodidae) are important parasites present in almost every geographic zone 
in the world. Ticks are vectors of (viral, bacterial, and protozoal) pathogens that cause 
disease in humans and animals worldwide (de la Fuente et al., 2008). The deep 
knowledge of the incidence and prevalence of the tick species involved in the 
transmission, as well as their geographical distribution, would be very important for the 
control of tick-borne diseases (TBDs). Several species of ticks are indigenous in Italy 
and have been reported to infect companion and production animals as well as humans.  
A number of Spotted fever group Rickettsiae is associated with ticks and these 
pathogens can be transmitted both in trans-ovarian and trans-stadial way. The main 
vectors are ticks belonging to Dermacentor, Rhipicephalus, Haemaphysalis and Ixodes 
genera. 
Although Mediterranean spotted fever (MSF) due to Rickettsia conorii was thought for 
a long time to be the only tick-borne rickettsial disease present in Europe, five more 
spotted fever rickettsiae have been described as emerging pathogens in the last decade 
(Parola et al., 2004). Sicily is the Italian region with a high number of TBDs cases, 
probably due to particular climatic aspects. TBDs diagnosed in Sicily are mainly 
theileriosis, anaplasmosis, babesiosis, and other rickettsioses, besides bacterial and virus 
diseases (Caracappa et al., 1999). Every year, several outbreaks due to Theileria, 
Babesia or Anaplasma infections in cattle are recorded. Imported breeds are the most 
susceptible. 
Sicily represents a typical Mediterranean ecosystem to study tick infestations and the 
prevalence of endemic tick-borne pathogens (Torina et al., 2008a). Several studies have 
characterized the prevalence of tick-borne pathogens in vertebrate hosts in Sicily (de la 
Fuente et al., 2005a,b, 2006; Torina et al., 2007, 2008b). However, limited data are 
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available on the presence and prevalence of these pathogens in ticks (de la Fuente et al., 
2005a; Torina et al., 2008b, 2010). 
The aim of the study was to analyze tick species and pathogen interactions present in 
Sicily. In this study, we have analyzed ticks collected in Sicily in the last seven years.  
 
Materials and methods 
Ticks were collected in Sicily, during the period 2004-2010 by dragging vegetation or 
directly removed from hosts. A total number of 5349 PCRs were performed in ticks 
samples collected from infested animals (3703) or questing ticks (1646). All specimens 
were identified by morphological characters using standard taxonomic keys for Italian 
Ixodidae (Manilla, 1998) and kept alive for at least one week. It was previously 
demonstrated that ticks are able to clean the organisms by day 4 after being removed 
from a highly parasitized host (de la Fuente et al., 2001), ticks were thus disinfected and 
stored in 70% ethanol until rinsed with distilled water, and cut in sterile tubes prior to 
the processing. DNA from ticks was extracted using TriReagent (Sigma, St. Louis, MO, 
USA) following manufacturers recommendations. The DNA was resuspended in sterile 
distilled water and stored at -20°C until used. 
PCR with specific primer sets were used for detection of Anaplasma spp (Stuen S, 
2003), A.marginale (de la Fuente J, 2003), A.phagocytophilum (de la Fuente J, 2005c), 
Rickettsia spp. (Tzianabos T, 1989), Ehrlichia sp (Ulrike G, 1996) and Coxiella burnetii 
(To H, 1996) as previously described with 0.1–10 ng of  DNA using 10 pmol of each 
primer and the Ready-To-Go PCR beads (Amersham, Piscataway, NJ, USA). 
Reactions were performed in an automated DNA thermal cycler for 35 cycles. The PCR 
products were analyzed in 1% agarose gels to check the size of amplified fragments. 
Control reactions were performed without the addition of DNA in the reaction to rule 
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out contaminations during PCR. Positive PCR products for A.marginale were sent to 
Macrogen Inc. (Seoul, Korea) to confirm by sequencing the specificity of the reactions. 
Prevalence was calculated for each pathogen in different tick species. Data reported 
were referred to at least fifty ticks tested for each pathogen.  
Results  
After the identification step, ticks were classified as follows: Rhipicephalus (Boophilus) 
annulatus, Dermacentor marginatus, Haemaphisalis sulcata, Hae. punctata, Hyalomma 
lusitanicum, Hy. marginatum, Ixodes ricinus, Rhipicephalus turanicus, Rh. bursa, Rh. 
sanguineus. In Figure 1 are reported the tick species and pathogen interactions for 
Anaplasma, Ehrlichia, and Rickettsia species and for Coxiella burnetii.  
The pathogen Anaplasma spp was found in all the ticks species tested, the highest 
prevalence was calculated in Hy. marginatum (17,7%) followed by Rh. bursa, Rh. 
turanicus, D. marginatus and I. ricinus (prevalence ranging from 10,2% to 8,2%), while 
Hy. lusitanicum and Rh. sanguineus had prevalence value less than 2,0%. A. marginale 
was isolated only from Rh. bursa (3,8%) and Rh. sanguineus (2,8%). Interestingly, A. 
phagocytophilum, was detected in Hy. marginatum (15,0%) Rh. turanicus (9,4%), Rh. 
bursa (6,1 %). I. ricinus had a prevalence of 5,7%. Ehrlichia spp showed a highest 
prevalence in D. marginatus (9,4%). As concerns Rickettsia spp prevalence, D. 
marginatus (34,4%), Rh. sanguineus (29,9%) and Hy. marginatum (20,8%) were the 
tick species with highest values. The Rickettsia prevalence for all the other species 
ranged from 10,3% to 1,6%. Finally, C. burneti was mainly present in Hy. marginatum 
(8,9%) and Hae. punctata (6,3%). 
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Discussion 
During the last decade several studies on tick infesting animals have been carried out in 
Italy (Garippa and Sanna 1990; Di Todaro et al. 1999; Genchi and Manfredi, 1999; 
Georges et al. 2001; Cringoli et al. 2002; Beninati et al. 2004, 2005; Rinaldi et al. 
2004). In most cases, the above mentioned studies are related to occasional tick 
collections, i.e. 2–3 moth periods, and/or to one host only. 
Our study was conducted on ticks collected in Sicily, especially in the area near 
Palermo, where MSF, mainly due to R. conorii, has been endemic for long time.  
In a previous study, the clinical data of 176 MSF patients in a period ranging from 1996 
to 1999 were analysed (Picciotto et al., 2000). It was showed that an occupational risk 
exists among small farmers, but that there were also environmental risks for subjects 
living in rural areas due to contact with infected dogs or other animals. In Sicilian ticks 
(n.150) collected in 2001 and 2002 on livestock (Beninati et al. 2004, Beninati et al. 
2005) and analysed by polymerase chain reaction (PCR), was evidenced the presence of 
R. slovaca in D. marginatus and in Hae. punctata and R. aeschlimannii and R. africae 
in Hy. marginatum. 
The pathogenic role of R. slovaca in humans has been shown in France (Raoult et al., 
2002; Cazorla et al., 2003). It could be thus argued that our tick investigation has been 
an important stimulus to implement studies for better understanding human TBDs 
transmission in Sicily. 
The tick species identified in this study have been previously associated with pathogen 
transmission. Recent surveys carried out in Sicily on haemoparasites transmitted by 
ticks to cattle have shown a very high prevalence of mixed infections: Babesia spp. 
and/or Theileria spp. and/or Anaplasma spp. (Loria et al. 1999; Greco et al. 2000; 
Sparagano et al., 2000; Georges et al.. 2001) or Anaplasma, Ehrlichia and Rickettsia 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
spp. were detected in H. marginatum ticks collected from cattle (Torina et al., 2010). 
Some species sampled can also transmit Rickettsia to humans and animals. In fact, R. 
conorii, causative agent in Europe of Mediterranean Spotted Fever (MSF), was detected 
in R. sanguineus, but also in R. turanicus and in D. marginatus (Torina et al 2010). R. 
slovaca, responsible for the human disease known as tick-borne lymphadenopathy is 
found in D. marginatus and other spotted fever group rickettsiae are present in H. 
marginatum (Beninati et al. 2005). 
Ticks in Sicily play an important role in the transmission of vector-borne diseases for 
humans and animals. 
We confirmed that Rickettsia infection is common in ticks found in Sicily. In fact, the 
presence of Rickettsia was detected in all the eight tick species found in the area, and 
that D. marginatus could play a relevant role in Riclettsia transmission rather than R. 
sanguineus that shows high prevalence but is a less anthropophilic tick.  
The high prevalence in the ticks species tested for Anaplasma and Rickettsia pathogens 
could be due to the high number of pathogens belonging to the two genera circulating in 
Sicily while Coxiella Burnetii and Ehrlichia have lower prevalence. 
The characterization of tick-borne pathogens in ticks suggested differences in the role 
that different tick species play in the pathogen life cycle and transmission. This 
information is important for epidemiological studies of tick-borne pathogens in Sicily 
and to evaluate the risks associated with pathogen transmission to humans and animals. 
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Legend to Figures 
 
Figure 1. Tick species identified in Sicily from year 2004 to 2010 and detection of 
Anaplasma, Ehrlichia, and Rickettsia species and Coxiella burnetii expressed in 
prevalence. 
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Introduction
Babesiosis is one of the most common infections of
free-living animals worldwide. The disease is caused by
intraerythrocytic parasites of the genus Babesia. Babesia
bigemina is a cattle pathogen that is transmitted by the
tick vector, Rhipicephalus (Boophilus) spp. Babesiosis is
one of the major causes of economic losses in the cattle
industry in the tropical and subtropical countries.
Although an attenuated strain of the parasite is still
used as a vaccine in some countries of the world, this
strain poses risk of reverting back to the wild type, and
thus causing outbreaks of babesiosis. Therefore, this
research is focused on molecular aspects of B. bigemina to
identify and study the surface molecules that could be
used to induce a protective immune response in cattle
and could be incorporated into a subunit vaccine for con-
trol of babesiosis.
The design of anti-babesial vaccines has been hampered
by extensive polymorphisms in some parasite proteins,
particularly those expressed on the surface of the parasite.
Many identified or suspected molecules may be involved
in the erythrocyte invasion and may be targets for the
development of vaccines, but few are characterized in
B. bigemina. One of these recently identified invasion
molecules, apical membrane antigen 1 (AMA-1), is a
trans-membrane antigen.
The most characterized AMA-1 protein is the one codi-
fied by Plasmodium falciparum (PfAMA; Peterson et al.,
1989). This protein has been extensively studied because,
among the few anti-malarial vaccine candidates under
development, it was one of the most promising erythro-
cyte stage candidates (Latitha et al., 2008). PfAMA-1 is a
protein of 622 residues and a molecular weight of
83 KDa and three major domains defined by eight disul-
phide bonds (Escalante et al., 2001; Deans et al., 1988;
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Summary
Babesia bigemina is a parasite endemic in different parts of the world, including
Europe and the Americas. One of the few genes characterized in this species
codifies for the Apical Membrane Antigen 1 (AMA-1), a trans-membrane anti-
gen recently identified. In this research, we characterized the ama-1 gene from
three Italian B. bigemina strains, two B. bigemina strains obtained from Ragusa,
Sicily (ITA1 and ITA3) and a third one obtained from Benevento, Campania
(ITA2). Italian sequences were compared with those of the Australian strain
obtained from the Sanger Institute web site and to strains from different parts
of the world. The results obtained confirmed that this newly described ama-1
gene is highly conserved among Italian and foreign strains which has implica-
tions for vaccine development.
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Hodder et al., 1996). In 2004, Eric de Vries et al.
(reviewed by Gaffar et al., 2004) identified and character-
ized the B. bovis AMA-1 protein (BbAMA-1). They
reported that the 62.2 kDa protein aligned with the full-
length sequence of P. falciparum, Plasmodium vivax and
Toxoplasma gondii, and had structural features similar to
those of other AMA-1 proteins. As has been the case with
several other Apicomplexa, AMA-1 is thought to play a
crucial role in the invasion of erythrocytes by Babesia
bigemina parasite (Yokoyama et al., 2006).
This study reports on features of B. bigemina AMA-1
gene from Italian strains of the parasite, and provides
predictive information obtained using bioinformatics
tools related to the protein.
Materials and Methods
Research on putative B. bigemina antigens from closely
related microorganisms
The research is based on the data from the related micro-
organisms, Plasmodium and B. bovis, as well as on the
valuable tool available in the Sanger Institute web site
which provides published raw data derived from the
B. bigemina whole-genome sequencing project. Through
this tool, it was possible to compare genes of related organ-
isms with the B. bigemina genome, thus allowing for iden-
tification of conserved sequences. In this manner, a region
corresponding to AMA gene was identified in B. bigemina.
This region was submitted to two different software:
ORF Finder (available at http://www.ncbi.nlm.nih.gov/
projects/gorf/) and ORF Finder (available at http://
www.bioinformatics.org/sms/orf_find.html) to confirm that
the sequence was a complete ORF without stop codons in
frame. Once detected, the correct start and stop codons
were determined and amplification was preformed.
Blood and spleen DNA extraction
Genomic DNA from B. bigemina naturally infected calves
was extracted using the Sigma GenElute Mammalian
Genomic DNA miniprep kit (Sigma-Aldrich Inc., St
Louis, MO, USA), according to the manufacturer’s
instructions. Out of three samples, which resulted positive
at the diagnostics PCR (Figueroa et al., 1993), two were
obtained from whole blood, and one from a spleen-
extracted post-mortem by a bovine died of Babesiosis.
Amplification of the gene codifying for the surface
antigen
The primers for the amplification of AMA were designed
using the available sequence in the Sanger Institute web
site (http://www.sanger.ac.uk/cgi-bin/blast/submitblast/
b_bigemina). The primers were designed in such a way
that the amplified region contained the entire ORF (Mos-
queda et al., 2008).
Cloning of the PCR products and sequence analysis
Purified PCR products were cloned in Invitrogen pCR2.1
TOPO TA cloning vector (Invitrogen Inc., Carlsbad, CA,
USA), according to the manufacturer’s instructions.
Six positive colonies were chosen, from which plasmid
DNA was extracted using the Promega Wizard SV Mini-
preps DNA purification system (Promega Inc., Madison,
WI, USA). Plasmids obtained in such a way were
restricted with EcoRI, quantitated and sent to Macrogen
Inc. (Seoul, Korea) for sequencing. Sequencing was per-
formed in the forward and reverse direction, using M13F
and M13R universal primers. It was necessary to adopt
the technique of primer walking because the fragment
was too long to be sequenced.
The sequences were then aligned using the software
ClustalW2.0.10 (Larkin et al., 2007) and Bioedit (Tom
Hall Ibis Biosciences, Carlsbad, CA, USA).
The software, MEGA (Kumar et al., 2008; Tamura
et al., 2007) and DAMBE (Xia and Xie, 2001; Xia, 2000),
was used to calculate the percentage of similarity among
each of the analyzed sequences. All results are based on
the pairwise analysis of the sequences. Analyses were con-
ducted using the Maximum Composite Likelihood
method in MEGA4. To obtain the main predictive
features of the protein, the sequence was submitted to
EXPASY proteomic server (Gasteiger et al., 2003).
Each aminoacidic sequence was analyzed to seek
the sequence of possible signal peptides using the
SignalP software (Center for Biological Sequence Analysis,
University of Denmark, Copenhagen, Denmark), the pres-
ence of possible trans-membrane helixes using TMHMM
software (Center for Biological Sequence Analysis), puta-
tive B-cell epitopes (Predicting Antigenic Peptides, avail-
able at http://bio.dfci.harvard.edu/Tools/antigenic.pl) and
hypothetical disulphide bonds (DiANNA 1.1 web server –
Ferre and Clote, 2005a,b).
Results
The whole coding region of the AMA-1 gene was ampli-
fied and sequenced from three Italian strains of Babesia
bigemina. The sequences were submitted to GenBank with
accession numbers GQ257738, GQ257739 and GQ257740.
The full-length AMA-1 gene of 1788 bp encodes a 595
amino acids product similar to the 622 aminoacids AMA-
1 product of P. falciparum and to the 605 aminoacids
AMA-1 product of B. bovis. The molecular weight of the
Italian strain protein results 65.9 kDa (EXPASY).
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Comparison of Babesia bigemina AMA-1 to the
B. bovis and P. falciparum AMA-1 proteins
A consensus sequence was obtained by the comparison of
the three Italian sequences that resulted in a high degree
of identity. To verify the degree of conservation of
AMA-1 protein among different Apicomplexa, the amino-
acidic sequence of B. bigemina AMA-1 was compared
with those of B. bovis and P. falciparum.
The percentage of similarity of B. bigemina AMA-1 with
P. falciparum AMA-1 was low (28.12%; ClustalW2.0.10),
but some of its features are typical of AMA-1 family mem-
bers, among which the TM helix, the short-cytoplasmic
tail, and a putative structural/functional conservation. The
functional homology between PfAMA and B. bigemina
AMA-1 protein was strongly supported by the results
obtained using EPipe Server (Tress et al., 2007) and
P-Fam (Finn et al., 2008) that included the protein in
AMA-1 family. The hydrophobic N-terminal domain of
B. bigemina AMA-1 protein was predicted to form a signal
peptide (SignalP) of 30 amino acids, that can be found
also in PfAMA-1 (24 a.a.) and BbAMA-1 (39 a.a.).
A bioinformatic study was conducted using DiANNA
1.1 web server (Ferre and Clote, 2005a,b) to predict hypo-
thetical disulphide bonds occurring in the Italian strain.
The results showed 16 cysteine residues putatively
involved in disulphide bridge formation. The multi-
sequence alignment (ClustalW2.0.10) of B. bigemina, B.
bovis and P. falciparum AMA-1 proteins (Fig. 1) demon-
strated that most of the cysteine residues forming disul-
phide bonds in P. falciparum AMA-1 (13 of 16) are
conserved in the three organisms which strongly supports
the hypothesis of a structural and functional homology
among AMA-1 proteins.
Fig. 1. Multiple-sequence alignment of AMA-1 proteins of B. bigemina (BbigAMA), B. bovis (BbovAMA) and Plasmodium falciparum (PfAMA).
‘‘*’’ means that the residues in that column are identical in all sequences in the alignment. ‘‘:’’ means that conserved substitutions have been
observed, ‘‘.’’ means that semi-conserved substitutions have been observed. Cysteine residues that form disulfide bonds in P. falciparum AMA-1
are marked and coupled by numbers.
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Comparison of Italian B. bigemina AMA-1 sequences
with the Australian strain
The Italian strains sequences were compared with the cor-
responding Australian strain sequence. Because of the
complete sequence genome, the Australian strain is pres-
ently considered as a reference strain. From the three
sequences analyzed, the variation in the AMA-1 gene, at
the nucleotide level, shows point mutation at 54 positions
along the length of the gene. Out of these, 36 are synony-
mous mutations and 18 are non-synonymous changes.
Fifteen mutations occur at the first base of codon, 4 at
the second base and 35 at the third base of the codon.
Analysis of the amino acid substitutions in the AMA-1
protein revealed a total of 18 amino acid changes across
the length of AMA-1 protein. The analysis of the amino-
acidic sequence of the protein by means of TMHMM
software, revealed the presence of a TM helix between
amino acids 513 and 531 near the C-terminus. The helix
divides the extracellular portion of the protein (amino
acids 1–512) from the predicted short cytoplasmic C-ter-
minal tail (532–595). Out of the 54 mutations, the most
of them (51) occurs in the extracellular part of the
protein, two occur in the cytoplasmic tail, while the
trans-membrane region has only a synonymous mutation.
The average percentage of identity among the Italian
and the Australian strains was calculated to be 99.984%,
whereas among Italian sequences only is 99.986%.
Comparison of B. bigemina AMA-1 sequences among
Italian and foreign strains
The comparison of the sequence of B. bigemina AMA-1
gene in the Italian strains to those coming from other
Countries (Mexico-personal communication- and Argen-
tina – GenBank AB481200) and to that one from a strain
provided by VMRD Inc. (Pullman, WA, USA; lot
V02064) demonstrated a high degree of similarity. The
overall average of identity at the nucleotide level resulted
99.98%. The overall average of homology at the aminoac-
idic level was 99.99% (data not shown).
Prediction of antigenic peptides
The 565-aminoacid sequence of the Italian mature protein
(consensus sequence) was submitted to the Predicting
Antigenic Peptides software to search for B-cells epitopes.
Nineteen different peptides were identified by the soft-
ware. Of these, 14 were conserved among Italian and Aus-
tralian strains (data not shown), but the position of the
peptides in the quaternary structure of the protein, their
antigenicity and their real efficiency to induce protection
against challenge, require further investigation.
Discussion
The AMA-1 protein is an apically located protein that is
shared by many apicomplexan organisms and that has a
role in the host red blood cells invasion process. The
AMA-1 family members exhibit significant common
features and have been studied extensively to understand
whether they could be considered as antigens to be
included in a subunit vaccine. Studies based on synthetic
peptides of PfAMA-1 have indicated that they elicit a
specific immune response in humans naturally exposed to
malaria parasites (Lal et al., 1996).
Antisera directed against BbAMA-1-derived peptides
specifically reduced the in vitro invasion efficiency of
B. bovis, indicating that AMA-1 is indeed located on
the surface of merozoites and is accessible to antibodies
(Gaffar et al., 2004).
Babesia bigemina AMA-1 protein, a newly identified
surface antigen, has several common features with other
AMA-1 family members and exhibits also a high degree
of similarity with the orthologue gene of B. bovis. A com-
parison among Italian strains of B. bigemina demon-
strated a high degree of both nucleotide and aminoacidic
identity. Moreover, several putative antigenic peptides
were detected and they could be used for investigation of
the recognition by specific antibodies. These preliminary
data provide basis for further study of the B. bigemina
AMA-1 antigen and its possible inclusion in a subunit
vaccine for control of bovine babesiosis.
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